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Abstract
Evolutionarily conserved signalling intermediate in Toll pathways 
(ECSIT) was identified orginally as a TNF receptor associated factor 
6 (TRAF6) interacting partner. The murine homolog mECSIT has 
been shown to be involved in NFκB, MAPK, BMP and mitochondrial 
signalling. To date there is no work published on the human 
homolog, hECSIT. In this thesis, I present data indicating that hECSIT 
is involved in NFκB, BMP and MAPK signalling. There is a striking 
difference in the role of hECSIT and mECSIT in the activation of 
inflammatory transcription factors NFκB, ELK-1 and AP-1; with 
mECSIT augmenting their activation and hECSIT having an inhibitory 
role. In addition I demonstrate that hECSIT specifically targets the 
p42/44 branch of MAPK signalling. Suppression of endogenous 
hECSIT results in increased basal and proinflammatory induced 
phosphorylation of p42/44 but not JNK or p38. Thus, hECSIT 
signalling represents a novel means of regulating p42/44 and its 
downstream targets.
vii
1. Introduction
1.1 The Immune System
Multicellular organisms are constantly faced with the challenge of 
microbial invasion. The ability to sense and eradicate microbes is 
essential  for survival.  This is  mediated by the immune system, a 
highly  complex  and  adaptable  system.  The  immune  system  of 
vertebrates is broadly divided into two distinct elements, the innate 
and the adaptive immune systems (Moresco et al., 2011). 
The innate immune system is evolutionary ancient. It is the first line 
of  defence  against  microbe  infection  and  is  critical  to  their 
detection. It is characterised by germline encoded receptors which 
recognise conserved motifs of  pathogens to mount an immediate 
immune  response  .  The  cells  of  the  innate  immune  system, 
monocytes,  macrophages,  neutrophiles,  mast  cells  and  dendritic 
cells (DCs), induce inflammation, phagocytose pathogens, as well as 
modulating the adaptive immune response . The adaptive immune 
response is only present in vertebrates, it is activated in a delayed 
fashion  and  is  influenced  by  prior  exposure  to  an  antigen.  In 
comparison  with  the  germline  encoded  innate  receptors,  the 
receptors of the adaptive immune system are somatically generated 
by  DNA  recombination  within  variable  regions  and  are  highly 
specific even at molecular level. This results in a specific clonal cell 
response against a pathogen .
viii
1.2 Pattern Recognition Receptors
The  receptors  of  the  innate  immune  system are  termed  Pattern 
Recognition Receptors (PRRs). Three main categories of PRRs have 
been discovered,  the membrane bound Toll-like receptors  (TLRs), 
cytoplasmic  NOD  like  receptors  (NLRs)  and  Rig-I-like  receptors 
(RLRs) (Creagh and O’ Neill, 2006; Kawai and Akira, 2009; Takeuchi 
and  Akira,  2010).  They  are  activated  upon  recognition  of  their 
ligands,  which  are  broadly  classed  as  pathogen  associated 
molecular  patterns  (PAMPs)  and  danger  associate  molecular 
patterns (DAMPs) . PAMPs are molecular motives that are unique to 
pathogens, discriminating them from host proteins. They are highly 
conserved  and  essential  for  survival  of  the  microbe,  e.g 
lipopolysaccharide  (LPS)  of  gram  negative  bacteria  or  double 
stranded  RNA  (dsRNA)  from  viruses.  DAMPs  are  endogenous 
molecules released by the host in response to pathogenic infection, 
necrosis, injury or certain pathological conditions (Kawai and Akira, 
2009; Matzinger, 2002).  They include mitochondrial DNA (mtDNA), 
extracellular ATP, high mobility group box 1 protein (HMGB-1), uric 
acid and heat shock proteins (Piccinini and Midwood, 2010; West et 
al., 2011).
 Recognition  of  PAMPs  or  DAMPs  by  PRRs  triggers  cascades  of 
protein  signalling  leading  to  changes  in  gene  expression.  These 
cascades  are  highly  dependent  on  phosphorylation  and 
ubiquitination  as  a  means  to  alter  protein  activity  .  In  terms  of 
ubiquitination,  proteins  are  mainly  subjected  to  Lysine-48  linked 
polyubiquitination (K48 pUB) or Lysine-63 linked polyubiquitination 
(K63 pUB). In general K48 pUB is recognised by the 26s proteosome 
leading  to  protein  degradation,  while  K63  pUB  is  not  generally 
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associated with degradation and instead is more often used to form 
protein scaffolds (Bhoj and Chen, 2009; Chau et al., 1989; Chen and 
Sun, 2009; Deng et al., 2000; Pickart, 2001; Wang et al., 2001). The 
signalling  cascades  converge  on  transcription  factors  such  as 
nuclear  factor  kappa  β  (NFκB), activating  protein-1  (AP-1)  and 
interferon regulatory factors (IRFs)  which can then regulate gene 
expression . Depending on the PRR involved, signalling can lead to 
the  induction  of  proinflammatory  cytokines  and  chemokines, 
antiviral  proteins,  activation  of  the  complement  system and  the 
recruitment of phagocytic cells. Integration of signals from multiple 
PPRs, metabolic and environmental sensors determines the ultimate 
outcome of signalling . 
1.2.1 Toll-Like Receptors 
TLRs  are  the  most  widely  studied  class  of  PRR.  They  were 
discovered  in  the  1990’s  after  it  was  found  that  the  Drosophila 
protein  dToll,  which  was  known  to  be  involved  in  embryonic 
development,  played  a  role  in  Drosophila’s anti-fungal  defence 
(Lemaitre  et  al., 1996).  The  human  homologue  TLR4  was 
subsequently identified and was found to respond to LPS, lead to the 
activation of the proinflammatory transcription factor NFκB and the 
induction  of  proinflammatory  cytokines  (Hoshino  et  al., 1999; 
Medzhitov  et  al., 1997;  Poltorak  et  al., 1998).  Since  the  seminal 
work on TLR4, 10 TLRs have been discovered in humans and 13 in 
mice.  The  nature  of  the  PAMPs  detected  by  TLRs  is  diverse 
encompassing proteins, lipids, lipoproteins and nucleic acids derived 
from viruses, bacteria, fungi and protozoa (Akira  et al.,   2006 ; Kawai 
and Akira, 2010).
Structurally  TLRs  are  members  of  the  type-1  integral  membrane 
protein family. They are characterised by extracellular leucine rich 
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repeats (LRRs) involved in ligand detection, a single transmembrane 
domain and a cytoplasmic Toll/Interleukin-1 receptor (TIR) domain. 
The TIR domain of TLRs lacks enzymatic activity and must engage 
adaptor  proteins  to  propagate  signalling.  (;  .  Five  intracellular 
adaptor  proteins,  myeloid  differentiation  primary-response protein 
88  (MyD88),  MyD88  adaptor-like  (MAL)  ,  TIR-domain  containing 
adaptor protein inducing IFN-β (TRIF), TRIF-related adaptor molecule 
(TRAM)  and sterile α and HEAT-Armadillo motifs (SARM) , have been 
shown  to  act  as  adaptor  proteins  for  TLRs  and  can  orchestrate 
signalling to multiple proteins . The diversity of TLR signalling is in 
part  due  to  differential  engagement  of  these  adaptor  molecules 
(Kawai and Akira, 2010; Yamamoto  et al.,   2004 ).
 TLR signalling results in the activation of transcription factors such 
as  NFκB,  AP-1  and  IRF3/IRF7  which  induce  the  expression  of 
inflammatory  cytokines,  chemokines,  antiviral  proteins, 
antimicrobial products and co-stimulatory molecules. These induce 
local  and systematic inflammation but  furthermore are necessary 
for the activation and modulation of the adaptive immune system . 
Components of the TLR pathways form networks with each other 
and other signalling pathways to modulate the nature, magnitude 
and duration of innate immune responses (Kawai and Akira, 2010).
TLRs can be found on the cell surface (TLR1, TLR2, TLR4, TLR5 and 
TLR6)  or  on  internal  membranes,  such  as  endoplamic  reticulum, 
endosome,  lysosome  or  endolysosome  (TLR3,  TLR7.  TLR8,  and 
TLR9). Cellular location is important for the detection of ligands and 
distinguishing between host and non-host molecules. Additionally it 
can dictate the type of proteins activated and the resulting response 
.
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1.2.1.1 Cell Surface Receptors
TLR1, TLR2, TLR4, TLR5 and TLR6 are located on the cell surface. 
They recognise molecular components on the surface of the 
pathogens.
-TLR1, TLR2 and  TLR6
These TLRs are all located on the plasma membrane. TLR2 deficient 
mice fail to respond appropriately to several gram-positive bacteria 
cell wall components and are highly susceptible to Staphyloccocus 
aureus infection (Takeuchi  et al., 2000). TLR2 can respond to wide 
range of ligands, due to its ability to form heterodimers with TLR1 or 
TLR6.  As  homodimers  they  respond  to  lipoteichoic  acid  of 
gram-positive  and  gram-negative  bacteria,  Mycobacteria  cell  wall 
component lipoarrabinomannon, and fungal membrane component 
zymoson (Kataka  et al., 2002; Massari  et al., 2002; Wetzler  et al., 
2003).  TLR1  and  TLR6  homodimers  bind  triacetylated  and 
diacetylated  lipoproteins  of  bacterial  membranes  respectively 
(Takeuchi  et  al., 2002).  It  follows  that  TLR1/2  heterodimers  can 
recognise  triacetylated  lipoproteins,  in  addition  to  synthetic 
lipoprotein PAM3CSK4 (Takeuchi  et al., 2002; Wetzler et al., 2003). 
TLR2-TLR6 heterodimers recognise diactylated lipoproteins including 
mycoplasma liporproteins (MALPs) (Takeuchi et al., 2001). 
-TLR4
TLR4  signalling  is  important  for  antibacterial  defences.  It  is 
expressed on numerous cells  including  monocytes,  macrophages, 
DC,  mast  cells  and  intestinal  epithelial  cells  (Sallusto  and 
Lanzavecchia,  2002).  Importantly  it  can  have  cell  surface  or 
endosomal  location,  resulting  in  the  activation  of  two  different 
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signalling  pathways (Kagan  et  al., 2008).  Its  most  widely  studied 
ligand  is  LPS,  a  gylcolipid  component  of  gram-negative  bacteria 
(Miyake  et al., 2004), but it can also respond to LIPID A analogs, 
taxol, respiratory syncynal virus, fibronectin and heat shock proteins 
(Lien et al., 2000; Perera et al., 2001). Trace amounts of LPS can be 
recognised  by  the  body  to  produce  proinflammatory  cytokines, 
TNFα, IL-1β and IL-6. LPS recognition by TLR4 requires LPS to be 
bound by LPS binding protein  (LBP)  (Schumam  et  al., 1994),  the 
LBP-LPS complex is recognised by CD14, which in turn transfers LPS 
to TLR4 and its associated protein MD-2 (Schromm et al., 2001). 
-TLR5
TLR5  recognises  flagellin,  a  protein  required  for  gram  negative 
bacteria  mobility  (Hayashi  et  al., 2001;  Mizel  et  al., 2003).  It  is 
expressed  on  moncytes,  DCs,  T  cells,  natural  killer  cells  and 
epithelium  cells.  It  is  expressed  on  basolateral  side  of  intestinal 
epithelial  cells  to  detect  only  bacteria  that  have  crossed  the 
epithelium  (Akira,  2005).  Residues  386-407  of  the  extracellular 
domain of TLR5 bind flagellin directly, as mutation of these residues 
prevents flagellin recognition (Smith et al., 2003). 
-IL-IR.
IL-1R and its associate receptor IL-1RAcP should be mentioned in 
the  same context  as  TLRs  as  the  IL-1R  and  IL-1rAcP  contain  an 
intracellular TIR domain. They are cell surface membrane proteins 
and signal in a very similar fashion to cell surface TLRs through the 
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adaptor protein MyD88, resulting in the activation of NFκB and AP-1 
(Medzhitov, 2001).
1.2.1.2 Endosomal Receptors.
TLR 3,  TLR7,  TLR8 and TLR9 are important  for  host  detection  of 
viruses.  They  signal  from  the  endosomal  compartments  after 
trafficking from the ER (Leifer et al., 2004).  Nucleic acid sensing is 
often  the  only  means  of  detecting  viruses,  however  there  is  no 
distinction  between  host  and  viral  nucleic  acids. 
Compartmentalisation  of  these  receptors  to  the  endosome,  is  a 
strategy  to  prevent  them from responding  to  host  nucleic  acids 
which  are  excluded  from  the  endosome  (Diebold  et  al., 2006). 
Aberrant  response  to  host  DNA  may  be  the  basis  of  some 
autoimmune  diseases  (Leadbetter  et  al., 2002).  TLR7  and  TLR9 
signalling is further restricted by a requirement for their cleavage 
for efficient signalling. This requires acidification of the endosome, a 
necessary step in endosome maturation (Hacker et al., 1996). 
-TLR3 
TLR3 recognises viral PAMPs such as dsRNA and synthetic molecule 
PolyI:C and leads to the activation of IRF3 and NFκB to produce type 
I interferons (IFNs) critical for the antiviral response (Alexopoulou et 
al., 2001).  Its  restriction  to  the  endosomes  is  compensated  by 
cytoplasmic RLR receptors, which also recognise viral PAMPs in the 
cytoplasm (Yoneyuma et al., 2004). 
-TLR7 and TLR8.
TLR7 and TLR8 are highly homologous and are both expressed on 
the  X  chromosome  (Wang  et  al., 2006).  They  are  expressed  in 
endosomal  and  phagosomal  compartments  of  monocytes  and 
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neutrophils. They recognise ssRNA from the influenza virus, Sendai 
virus and azoquindine compound R-846 which is structurally related 
to nucleic acid to induce type 1 interferons. TLR7 can respond to a 
subclass  of  antiviral  compounds  including  imidazoquiline  and 
loxoribine (Demaria et al., 2010; Jurk et al., 2002). 
-TLR9
TLR9 recognises DNA that is unmethylated and contains 2’ CpG. The 
latter is characteristic of bacteria genomic DNA but not host DNA 
that  in  contrast  is  highly  methylated  and  contains  few  CpG 
elements. These differences allow TLR9 to distinguish between host 
and microbial DNA (Hemmi  et al., 2000). TLR9 can cooperate with 
TLR5 and TLR8 (Merlo  et al., 2007), while it can antagonise TLR7 
signalling  when  associated  with  it  (Wang  et  al., 2006).  In 
plasmacytoid DCs, TLR9 can recognise virus derived CpG DNA to 
induce an anti-viral response (Krug et al., 2004; Lund et al., 2003; 
Takeshita et al., 2001).
-TLR10/11 
TLR10 is  an orphan receptor;  its  absence in  mice has prevented 
determination  of  its  ligand.  It  is  expressed  in  the  spleen,  lymph 
nodes, thymus and may form heterodimers with TLR1 and TLR2 to 
recognise  lipoproteins  (Chuang  and  Ulevitch,  2001).  TLR11  is 
non-functional  in  humans,  in  mice  loss  of  TLR11  leaves  them 
susceptible  to  uro-pathogenic  E.  coli infection,  the  nature  of  the 
ligand is unknown but is thought to be proteinaceous in nature as 
treatment with proteinase K can prevent ligand recognition (Zhang 
et al., 2004).
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1.2.2 Nod-Like Receptors
The discovery of TLRs in the 1990s marked a transient leap in our 
understanding  of  innate  immune  signalling.  A  similar  landmark 
finding occurred in the following decade with the discovery of two 
novel families of cytoplasmic PRRs, the RLRs and the NLRs . These 
receptors can sense microbial and viral signals in the cytoplasm and 
induce  pro-inflammatory  and  anti-viral  responses  via  the 
transcription factors NFκB and IRF3/IRF7 and MAPK signalling  .
NLRs consist of a large family of cytoplasmic receptors that detect 
the  presence  of  PAMPs  and  endogenous  DAMP molecules  in  the 
cytoplasm . They are characterised by three distinct domains- the 
ligand sensing LRR domain, the oligomersation NACHT domain and 
a variable N-terminal effector domain, important for protein-protein 
interaction and initiation of signalling. Members of the NLR family 
are divided into four subfamilies based on the N terminal effector 
domain-  NLRA  containing  an  activation  domain  (AD),  NLRB 
containing a baculovirus inhibitor of apoptosis repeat (BIR) domain , 
NLRC  containing  a  caspase  activation  and  recruitment  domain 
(CARD) domain and NLRP which contain a pyrin (PYD) domain ; Ting 
et al., 2008). 
The NLRC subfamily includes the nucleotide oligomerization domain 
(NOD)  receptors-  NOD1  and  NOD2,  that  recognise  peptidoglycan 
constituents  mesodiaminopimelic  acid  (meso-DAP)   and  muramyl 
dipeptide  (MDP)   respectively  (Windheim  et  al., 2007)  to  induce 
NFκB and IRF transcription factors . Mutations in NOD2 have been 
linked  to  Crohn’s  disease  (Ogura  et  al., 2001). Consistently, 
macrophages lacking either NOD1 or NOD2 fail to produce cytokines 
following stimulation .
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The NLRPs are a large NLR subgroup containing a PYD domain. They 
form  part  of  multiprotein  complex  known  as  the  inflammasome 
which functions to activate caspase 1 and/or caspase 5 ; Martinon 
and Tschopp, 2004).  Three inflammasome complexes have so far 
been identified NLRP1, NLRP3 and NLRC4. The activation of caspase 
1 is required for the processing of members of IL-1 family- IL-1β, 
IL-18, IL-33 which are formed through TLR signalling, into a mature 
active form . In this manner, TLR and NLR crosstalk is vital for an 
appropriate immune response, as they complement and synergise 
each others actions. Activation of the inflammasome leads to the 
recruitment of ASC, which contains both CARD and PYD domains. 
ASC can in turn recruit Caspase 1 through CARD domain interactions 
(Cassel and Sutterwala, 2009; Tschopp and Schroder, 2010). 
NLRP3 can be activated in response to MDP, bacterial RNA and DNA 
viruses. Other elements such as gout related uric acid crystals, UV-B 
irradiation, and asbestos may activate NLRP3 through stimulation by 
reactive  oxygen  species  (ROS)  .  Activated  NLRP3  can  form  a 
complex with apoptosis-associated speck-like protein containing a 
caspase-recruitment domain (ASC) and CARDINAL - also known as 
CARD8  and  tumour  upregulated  CARD  containing  antagonist  of 
caspase 9 (TUCAN) - to recruit Caspase 1 . Activation of NLRP3 is 
enhanced  by  extracellular  ATP.  This  ATP  can  be  sourced  from 
bacteria or from dying cells and is recognised by the P2X7 receptor 
which acts on the pannexin-1 pore . The exact mechanism of how 
P2X7  dependent  activation  of  pannexin-1  enhances  NLRP3 
activation is unknown. It is postulated P2X7 engagement promotes 
pannexin-1 dependent K+ efflux, promoting PAMP delivery into the 
cytoplasm resulting  in  NLRP3  activation  ;  Nakahra  et  al., 2010). 
Mitochondrial signalling is important in NLRP3 functioning. Several 
mitochondrial  derived  DAMPs  have  been  implicated  in  NLRP 
activation such as mitochondrial DNA mtDNA, ROS mROS and ATP 
(Lyer et al., 2009; Tschopp and Schroder, 2010; Zhou  et al.,   2011 ).
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1.2.3 RIG-1 Receptors
The  second  class  of  cytoplasmic  PPRs  are  the  RLRs  which  are 
comprised of two members, ribonucleic acid (RNA) helicases retinoic 
acid  inducible  gene  1  (RIG-1)  and  melanoma  differentiation 
associated gene 5 (MDA5) . They are RNA helicases and can detect 
RNA derived from viruses such as paramyxovirus and influenza A to 
orchestrate antiviral responses through NFkB and IRF transcription 
factors ; Satoh et al., 2010; Yoneyama and Fujita, 2007). 
RIG-I contains tandem CARD domains at its N-terminus, a central 
DExD/H helicase domain and a C terminal repressor domain (RD) 
which binds RNA. Viral  recognition,  through RNA binding,  induces 
conformational  changes  in  RIG-1,  promoting  self  association  and 
interaction  with  downstream  CARD  domain  containing  proteins. 
MDA5 also contains tandem CARD domains and DExD/H domains, 
but it is unknown if its C terminus acts as a RD domain (Kato  et al.,   
2011).
 Engagement  of  RLRs  results  in  the  activation  of  NFκB  and  IRF 
transcription  factors  as  well  as  MAPK  leading  to  induction  of 
pro-inflammatory cytokines and type 1 IFN. RLR signalling is closely 
associated with mitochondria . A major target for RLR activation is 
the  adaptor  protein  mitochondrial  antiviral  signalling  adaptor 
protein  (MAVS)  also  known  as  IPS-1,  VISA  and Cardif,  which  has 
been shown to localise to the mitochondria.  MAVS contains an N 
terminal  CARD-domain  which  interacts  with  the  CARD domain  of 
RLRs  . MAVS-deficient mice have deficient activation of IRF3 and 
NFκB  and  induction  of  type  1  interferons  and  inflammatory 
cytokines by RIG-1 and MDA receptors (Kumar  et al., 2006). MAVS 
can activate NFκB to produce proinflammatory proteins by targeting 
complexes containing inhibitor of κB kinase (IKK) proteins and also 
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receptor  interacting  protein  1  (RIP-1).  Complexes  containing  IKK 
related  kinases  TANK-binding  kinase  1  (TBK1)  and  IKKi  and  also 
adaptor  proteins  TANK  and  NEMO,  can  signal  through  IRF 
transcription  factors  to  produce  an  antiviral  type  1  interferon 
response (Kawai et al., 2005; Meylen et al., 2005; Seth et al., 2005; 
Xu et al., 2005). Recently it has been shown that MAVS degradation 
post  activation  is  required  for  IRF  activation  by  RIG-1.  This  is 
dependent  on  the  E3  ligase  TRIM25,  which  ubiquitinates  MAVS 
resulting in its degradation.  This releases NEMO and TBKi into the 
cytosol to activate IRF proteins .
1.3 TLR Signalling.
TLR  signalling  is  dependent  on  the  selective  use  of  adaptor 
molecules  .  MyD88  and  TRIF  are  the  main  TLR  adapters  and 
orchestrate  two  distinct  pathways,  the  MyD88-dependent  and 
TRIF-dependent pathways (Kawai and Akira, 2008).  MyD88 is used 
by  the  IL-1R  and  all  TLRs  aside  from TLR3,  which  signals  solely 
through the adaptor TRIF (Adachi et al., 1998; Beutler et al., 2005; 
Takeda, 2003). MyD88 can directly interact with the TIR domains of 
TLRs,  with  the  exception  of  TLR2  and  TLR4  which  bind  MyD88 
through  the  adaptor  protein  MAL  .  The  primary  outcome  of  the 
MyD88 pathway is the activation of NFκB. TLR4 uniquely can signal 
via the MyD88-dependent and the TRIF-dependent pathways . The 
location of the TLR4 receptor governs which pathway is activated. 
When TLR4  is  present  on  the  cell  surface  it  signals  through  the 
MyD88-dependent  pathway.  TLR4  signalling  through  the 
TRIF-dependent pathway is proposed to involve the endocytosis of 
TLR4 to the endosome where it engages TRIF via the adaptor TRAM . 
Signalling by TLR3 and TLR4 through TRIF leads to the activation of 
the IRF transcription factors producing an antiviral response . The 
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adaptor  protein  SARM  can  negatively  regulate  the 
MyD88-dependent  and  TRIF-  dependent  pathways  .  The  duration 
and  magnitude  of  TLR  responses  must  be  tightly  regulated  to 
ensure the efficient removal of a threat while minimising damage to 
host cells. TLRs have evolved a system of highly intricate feedback 
loops,  which  induce  prompt  amplification  of  an  inflammatory 
response but importantly  will  in a delayed manner terminate the 
response. 
1.3.1 MyD88 Dependent Pathway:
The MyD88 dependent pathway primarily leads to the activation of 
the transcription factor NFκB and MAPKs, essential for mounting of 
an immune response . NFκB activation leads to the expression of a 
plethora of genes to induce an inflammatory response , while MAPKs 
are critical for the activation of transcription factors and stabilisation 
of  numerous mRNAs generated in  an NFκB dependent manner (; 
Tseng  et  al., 2010).  The primary regulation  of  NFκB comes from 
their  interaction with inhibitory IκB proteins,  which prevents their 
nuclear  localisation  .  Signalling  through  the  MyD88-dependent 
pathway  overcomes  this  negative  interaction  allowing  NFκB  to 
translocate to the nucleus to induce gene expression  (Figure 1.1) . 
Crystal  structures  of  TLRs  propose  that  ligand  binding  induces 
dimersation  and/or  oligomerisation  of  the  receptors,  or 
conformational changes in preformed dimers (Kang and Lee, 2011. 
This  results  in  rearrangement  of  the  TIR  domains  to  facilitate 
interaction with the C-terminus TIR domain of  MyD88.  Binding of 
MyD88 to the receptor exposes its N-terminus Death Domain (DD), 
which  can  interact  with  the  DD of  members  of  the  Interleukin-1 
receptor-associated  kinase  (IRAK)  proteins  to  form  a  signalling 
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complex known as the Myddosome (Burns et al., 2003; Medzhitov et 
al., 1998; Muzio et al., 1997; Suzuki et al., 2002; .
TLR2 and TLR4 signalling requires the adaptor protein MAL to couple 
MyD88  to  the  receptor  (.  Beyond  this  role,  MAL  signalling  has 
profound affects on TLR signalling. It is involved in induction of the 
transcription  factor  CREB  and  can  negatively  regulate 
TRIF-dependent  signalling  (Mellett   et  al.,   2011 ;).  MAL  activity 
requires cleavage of its C-terminus by Caspase 1  which is regulated 
by inflammasome complexes (Martinon  et al., 2002).  Inhibition of 
Caspase  1  prevents  LPS  activation  of  NFκB  .  IRAK  proteins  and 
suppressor of cytokine signalling 1 (SOCS-1) can phosphorylate and 
target  MAL for  degradation,  possibly  dissembling the Myddosome 
preventing  further  signalling  (Dunne  et  al., 2010;  Mansell  et  al., 
2006). 
Members  of  the  IRAK  family  are  essential  for  TLR  activation  of 
NFκB . Four IRAK family members are known, IRAK1, IRAK2, IRAK4 
and IRAKM . IRAKM is proposed to be a negative regulator of TLR 
signalling.  Knockout  of  IRAKM  results  in  increased  production  of 
proinflammatory cytokines in response to a variety of TLR ligands . 
IRAK4  is  the  predominant  member  of  the  family,  IRAK4  -/-  mice 
display  impaired  NFκB  and  MAPK  activation  for  all  TLRs  except 
TLR3 . The formation of the Myddosome is proposed to allow IRAK4 
to  autophosphorylate  itself  and  subsequently  phosphorylate  and 
activate  IRAK1  and  IRAK2  which  can  then  recruit  the  E3  ligase 
tumour necrosis factor receptor (TNFR)-associated factor-6 (TRAF-6) 
to the Mydossome . 
IRAK1  was  initially  proposed  to  be  the  kinase  involved  in  the 
activation of TRAF6 . However IRAK1 -/- mice produced unexpected 
results,  displaying  impaired  but  not  abrogated  NFκB  and  MAPK 
signalling  .  IRAK2  is  now  proposed  to  be  responsible  for  TRAF6 
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activation  .  It  was  for  a  long  time  considered  a  pseudokinase, 
however it has now been shown to activate TRAF6 even in IRAK1 
deficient  cells  .  Interestingly  IRAK2-/-  display  normal  early  NFκB 
activation  but  impaired  late  and  sustained  activation  and  also 
impaired induction of NFκB dependent cytokines. Double mutants of 
IRAK1  and  IRAK2  exhibit  profound  defects  in  NFκB  and  MAPK 
signalling. From these studies a model is now proposed where IRAK1 
is thought to be initially recruited to the Myddosome and activated 
by  IRAK4,  while  IRAK2  is  recruited  at  later  stage  to  sustain  the 
signalling .  
Phosphorylation  of  TRAF6,  induces  its  oligomerisation  and  its  E3 
ligase activity . It can work in conjunction with E2 enzymes, UBc13, 
UBCH5 or  UBCH7,  to form K63 pUB chains  on itself  and also on 
target  proteins  .  K63 pUB chains  can act  as molecular  scaffolds, 
recruiting  signalling  proteins  via  ubiquitin  binding  domains  (UBD) 
which are specific to K63 pUB chains . 
The K63 pUB chains of TRAF6 recruit the TAK1 complex to TRAF6 . 
The  TAK1  complex  is  composed  of  transforming  growth  factor-β 
(TGF-β)-activated  kinase-1  (TAK1)  and  associated  TGF-β  binding 
proteins  (TAB)  proteins,  TAB1,  TAB2  and  TAB3  .  The  UBDs  of 
TAB1/TAB2 facilitate the recruitment of the TAK1 complex to TRAF6. 
Recruitment  of  the  TAK1  complex  stimulates  conformational 
changes in TAK1 allowing it to phosphorylate and activate itself  ; 
Deng et al., 2000; Gohda et al., 2004; Hacker et al., 2006; Jiang  et   
al.,   2002 ;  Shibuya  et  al., 1996;  Sun  et  al., 2004;  Takaesu  et  al., 
2000). TAK1 is also ubiquitinated by TRAF6 (Hamidi  et al., 2011). 
TAK1  can  phosphorylate  IKK  proteins  and  MAPK  kinases  (MKK), 
resulting in NFkB, p38 and JNK activation ; Shirakabe   et al.,   1997 ; 
Wang et al., 2001). Modification of other members of TAK1 complex 
can regulate TAK1 activity.  Recently  IL-1β signalling  and osmotic 
stress were shown to lead to the O-GlcNaylation of TAB-1 which was 
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required for full TAK1 and NFκB activity and production of IL-6 and 
TNFα  .  In  vitro  studies  have  shown  that  the  TRAF6  mediated 
activation of TAK1 was dependent on unanchored K63 pUB chains 
generated by TRAF6. These are proposed to be bound by TAB2 to 
activate TAK1. The importance of the unanchored chains in vivo is 
still undetermined . 
However,  TAK1  activity  is  redundant  for  NFκB  activation.  In the 
absence of TAK1, JNK activation in response to TLR, TNFR and IL-1R 
signalling  is  completely  abolished.  IKK  signalling,  while  severely 
reduced,  was  not  completely  abrogated.  TAK1  independent  IKK 
activation  is  also  evident  in  TAK-1  deficient  B  cells,  as  NFκB 
activation is comparable to WT upon BCR ligation (Sato et al., 2005). 
Furthermore  TAB1  deficient  mouse  embryonic  fibroblasts  (MEFs) 
show unimpaired activation of MAPK and NFκB in response to IL-1β , 
LPS and TNFα, despite the lack of TAK1 activity ; Mendoza  et al., 
2008). MEKK3 is a candidate for this TAK1 independent activation. 
MEKK3 is critical to TLR8 pathway . TLR8 signalling to NFκB and JNK 
is completely abolished in MEK3K deficient MEFs but unimpaired in 
TAK1 deficient MEFs.  In IL-1β signalling, the activation of NFκB is 
initially  mediated  through  TAK1  but  TRAF6  can  subsequently 
activate  NFκB  through  MEKK3,  independent  of  TAK1  activity. 
Activation of both is required for sufficient production of cytokines. 
In macrophages, TLR4 signalling requires MEKK3 for the induction of 
IL-6 and GMCSF, but not TNFα or IL-1β. The importance of TAK1, 
MEKK3 or another kinase in the activation of NFκB and MAPKs may 
be ligand and cell type specific ; ; 
The IKK complex is also recruited to the K63 pUB chains of TRAF6, 
where it is activated by TAK1 or another TRAF6 dependent kinase. 
Three canonical IKKs have been found, IKKα, IKKβ and IKKgamma 
(NEMO),  as  well  as  IKK-related  proteins,  TBK1  and  IKKi.  The  IKK 
complex,  composed of  IKKα, IKKβ and NEMO, binds the K63 pUB 
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chains of TRAF6 via the UBD of NEMO ; . This is postulated to bring 
IKKα and  IKKβ  into  close  proximity  to  TAK1,  facilitating  TAK1  to 
directly phosphorylate and activate the IKK complex. 
Members of the IKK complex work in conjunction to phosphorylate 
the  IκB  proteins   IKKα  functions  primarily  in  the  noncanonical 
pathway of NFκB activation . IKKβ is the major kinase response for 
phosphorylation  of  IκB.  IKKβ  deficient  mice  exhibit  severe  NFκB 
defects . The regulatory element NEMO is critical to NFκB activation 
and is  modified  with  K63 ubiquintin  chains  upon TLR signalling  . 
Mice  depleted  of  NEMO  no  longer  activate  the  IKK  complex  ; 
Schmidt-Supprian   et  al., 2000) Interestingly,  it  was  found  that 
NEMO is modified with and can also bind free linear pUB chains, to a 
100-fold  higher  degree  than  K63 pUB chains  .  These  chains  are 
generated by the E3 ligase LUBAC. In MEFs deficient for HOIL1, a 
component  of  LUBAC,  IL-1β  signalling  is  impaired  but  not  fully 
abrogated  .  It  is  proposed  that  formation  of  linear  chains  is  not 
necessary  for  initial  IKK  activation  but  may  enhance  its  activity. 
Linear chains conjugated to NEMO proteins, may be bound by other 
NEMO  proteins,  potentially  bringing  IKKβ  members  into  close 
proximity allowing them to transphosphorylate each other . 
NFκB activation is regulated  by IκB proteins . There are two main 
members of the IκB protein family, IκBα and IκBβ, but there are also 
atypical  IκB  proteins  BCl3,  IκBL  and  IκBNS  .  Their  activity  is 
mediated through their multiple ankrin repeats which can bind to 
NFκB dimers and interfere with nuclear localisation sequence (NLS) 
of NFκB. Different IκBs have varying affinities for NFκB dimers. IκBα 
binds  RelA-p50  with  highest  affinity,  while  IκBβ  binds  RelA 
homodimers. IκBα can mask the NLS of RelA but not the NLS of p50, 
however  it  has  nuclear  export  signal  (NES)  and  prevents  NFκB 
activity  by  shuttling  dimers  out  of  the  nucleus,  preventing  gene 
expression . IKK activation results in the phosphorylation of IκB on 
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Ser32 and  Ser36,  resulting  in  K48 linked  pUB on  Lys  19  by  the 
Skp1/cullin/F-box β-transducin repeat-containing protein (SCFβTRCP) 
and  subsequent  degradation  by  26s  proteosome  .  The  NFκB 
subunits  can  then  translocate  to  the  nucleus  to  promote  gene 
transcription,  they  mediate  the  transcription  of  genes  with  a  κB 
element  in  their  promoter  including  TNFα,  IL-1β,  IL-6  and  IL-10. 
Importantly NFκB signalling also induces the transcription of NFκB 
inhibitory proteins, such as A20 and IκB .
.    
Posttranscritptional regulation of gene expression is also important 
in TLR signalling. The stability of mRNA can be targeted as means to 
regulate  protein  levels,  as  can  translational  efficiency.  Many 
cytokine mRNA transcripts contain 3’ untranslated regions known as 
AU-rich elements (3’ UTR AREs), which can target mRNA for decay. 
Proteins can bind to these elements and influence the stability of 
the transcript. RNAses, such as MCPIP and ZC3H12a, can target the 
rate of mRNA decay. MAPK play large part in this posttranscriptional 
regulation . 
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Figure  1.1  TLR4-MyD88  signalling.  Upon  TLR  engagement,  Myd88  is 
activated resulting in activation of IRAK proteins, which in turn activate the E3 
ubiquitin ligase TRAF6. TRAF6 activates TAK1, phosphorylates IKKβ, activating the 
IKK complex to phosphorylate IκB leading to IκB degradation and release of NFκB. 
TAK1 also activates  the  MAPKs,  resulting  in  activation  of  AP1.  NFκB and AP-1 
transcription factors induce transcription of proinflammatory cytokines, such as 
TNF-α and IL-1. Taken and modified from Zhou et al., 2011.
1.3.2 TRIF-Dependent Pathway
The  MyD88-independent  or  TRIF-dependent  signalling  can  be 
activated by TLR4 and TLR3 stimulation .  It  was discovered from 
studies on MAL and MyD88 deficient cells which displayed delayed 
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activation  of  NFκB following  TLR3 and TLR4 engagement .  While 
TLR3  can  interact  directly  with  TRIF,  TLR4  requires  the  adaptor 
TRAM . TRIF signalling by TLR3/TLR4 leads to the activation of NFκB 
and  IRF  transcription  factors  to  induce  type  1  interferons  and 
cytokines such as TNFα, IL-6 and IL-12 .
TRIF dependent activation of NFκB involves the recruitment of RIP1. 
TRIF contains a C terminus RIP homotypic interaction motif (RHIM) 
domain which can interact with RIP1. The RIP1-TRIF interaction is 
essential for TLR3 and TLR4 induction of NFκB , It is proposed that 
upon TLR3 stimulation, RIP1 interacts with TRIF and is 
polyubiquitinated which recruits TRAF6 and TAK1 to TLR3. IRAK2 has 
been shown to directly bind to TLR3, and is involved in its activation 
of NFκB but not IRFs. The mechanism underlying this is unknown . 
TRAF  proteins  are  central  to  TRIF  dependent  IFN  production  . 
Compared  to  WT  mice,  TRAF3-/-  mice  have  lower  IFN  and  IL-10 
levels  following  TLR3/4/9  stimulation,  while  they  display  higher 
proinflammatory cytokines . The activation of type 1 interferons is 
dependent on the activation of IRF transcription factors, IRF3/7. IFNα 
is mainly dependent on IRF7, while IFNβ is dependent on IRF3, NFκB 
and c-jun/ATF2 . TLR4-TRIF signalling induces only IFNβ, while TLR3 
signalling  results  in  IFNα/β  .  Induction  of  IRF3  requires  the  N 
terminus of TRIF, which can associate with TRAF3 and the adaptor 
protein  NAK-assocaited  protein  1  (NAP1)  .  TRIF  signalling  is 
proposed  to  induce  autoubiquitination  of  TRAF3  with  K63  pUB 
chains,  facilitating  interaction  with  and  activation  of  IKK  related 
kinases, TBKI and IKKi, which can in turn phosphorylate IRF3 on its C 
terminus transactivation domain ; Saha  et al.,   2006 . Phosphorylated 
IRF proteins can form homodimers, translocate to the nucleus and 
induce gene expression . In addition the MAPK JNK has been shown 
to phosphorylate  IRF3 on its  N terminus.  Use of  the specific  JNK 
inhibitor  SP600125  severely  impaired  IRF3  mediated  gene 
xxvii
expression in response to LPS and PolyI:C, . Thus phosphorylation of 
IRF3 by TBK1 and JNK, on its C and N terminus respectively, may be 
required for full IRF3 activity. MyD88 signalling has been shown to 
activate the IKK related kinases without activating IRF3, indication 
an  additional  factor  other  than  IKK  related  kinases  activation  is 
required  for  IRF3  induction.  TRAF3  targeting  to  the  endosome is 
proposed to be a factor  .  Futhermore MyD88 and MAL signalling 
have been shown to block TRIF dependent activation of JNK, which 
may in turn prevent IRF3 activation . TRIF also contains TRAF6 and 
TRAF2  binding  sites.  Simultaneous  mutation  of  both  these  sites 
abrogated TRIF  signalling  to both  NFκB and IRF3.  Following  from 
these results it was found that TRAF2 and TRAF6 bind to TRIF and 
induce its polyubiquination with K63 chains, this leads to activation 
of IFN-inducible pathway .
It  appears  TRAF3 can have positive and negative affects  on TLR 
signalling,  that may be dependent on its  cellular  location.  TRAF3 
positively  regulates  TLR4  and  TLR3  induction  of  IFNs.  It  also 
positively  regulates  TLR9  mediated  activation  of  IRF7  and 
interferons  (Hacker  et  al., 2006;  Oganesyan  et  al., 2006).  These 
signalling events all occur at the endosome. In contrast, signalling 
by TLR4-MyD88, CD40 and TNFR1 signalling all occur proximal to 
the  membrane  and  are  negatively  regulated  by  TRAF3,  which 
inhibits the release of MAPKKK from signalling complex to activate 
MAPK ( Hacker  et al., 2006; Matsuzawa  et al., 2009; Tseng  et al., 
2010).   It  seems  TRAF3s  role  is  dependent  on  the  individual 
receptors,  receptor  location  and  also  the  adaptors  they  engage 
(Hacker at al., 2011). 
Cell surface activation of the IKK related proteins by IL-1β and TNFα 
can negatively regulate the activation of  IKK proteins.  IKK-related 
kinases are activated by IKK proteins in vitro in response to IL-1β, 
LPS and TNFα. In addition LPS and IL-1β can activate IKK-related 
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proteins independently of IKKs, involving an as yet unknown protein 
or may involve autophosphorylation of IKK related proteins (Clark et 
al., 2009) The IKK related proteins can inhibit the activation of IKK 
proteins, limiting their activation and thus their downstream targets 
such as NFκB (Clark et al., 2011). It is proposed that TANK promotes 
IKK related protein interaction with NEMO and TRAF6, to inhibit their 
activity and thus inhibit IKK proteins (Clark et al., 2011).
1.3.4 NFκB
NFκB is a master regulator of inflammation. It is elicited by viral and 
bacterial  infection,  inflammatory  cytokines  and  engagement  of 
antigen  receptors.  Environmental  and  physical  factors  can  also 
induce NFκB. NFκB induces transcription of a plethora of genes to 
promote proinflammatory and prosurvival responses . In mammals 
there are five members of the transcription factor NFκB family: RelA 
(p65), RelB and c-Rel and precursor proteins p105 (NFκB1) and p100 
(NFκB2),  which  are  processed  into  p50  and  p65  respectively  by 
degradation of C’ IκB-like ankrin repeats. They are characterised by 
a N terminus RHD domain which functions in dimerisation, nuclear 
tranlocation,  DNA  binding  and  interaction  with  inhibitory  IκB 
proteins. The act as hetero and homo dimers, binding to κB sites in 
the  promoter  region  of  target  genes  to  influence  their  gene 
expression.  RelB  primarily  binds  p100/p52,  while  RelA  and  c-Rel 
form dimers with p50. Some dimer combinations can have inhibitory 
effects  on gene expression.  The κB sites  are found in  numerous 
proinflammatory genes and thus NFκB activation can have profound 
affects on the cell . Targets genes include ones encoding cytokines; 
IL-Iβ,  IL-6,  IL-10,  TNfa,  chemokines;  MIP-1a/b,  cell  adhesion 
molecules; I-CAM, V-CAM, regulators of apoptosis; ASC, Bcx, BCl-xl, 
Bcl-2, BiM, c-FLIP. Others notables include MHC molecules required 
for  antigen  presentation  by  APC,  iNOS  and  MMPs.  Crtically,  κB 
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elements are present in promotors of genes for proteins such as A20 
and   IκB,  which  negatively  regulate  NFκBs  activity  to  control 
inflammatory responses 
1.3.5 IRF Transcription Factors
The  antiviral  interferon  response  is  primarily  regulated  by  the 
transcription  factors  IRF3  and IRF7 . The phosphorylated form of 
IRFs can dimerise and translocate to the nucleus to induce type 1 
IFNs  and  expression  of  IFN-inducible  genes.  IRF3  proteins  are 
constitutively and ubiquitously  expressed across many cell  types. 
Upon phosphorylation and dimerisation they can translocate to the 
nucleus and interact with CBP/p300 proteins to induced expression 
of target genes. All IRF target genes contain an interferon-sensitive 
response element (ISRE) domain in their promoter.  IRF3 primarily 
leads to the induction of IFN-β, while IRF7 predominately induces 
IFNα IRF7.  IRF7 expression is low in most cells compared with levels 
of IRF3 proteins. However IRF7 is an IFN-inducible gene and forms 
an autocrine positive feedback loop which leads to the expression of 
IRF7 through IFNR ;  Sato  et  al., 2000).  An unexpected finding in 
IRAK1-/- mice was that in pDCs TLR7 and TLR9 induced IFNα was 
completely abolished, proposing a role for IRAK1 in IFNα production. 
Furthermore  in  vitro IRAK1  has  been  shown  to  directly 
phosphorylate IRF7.  This pathway produces significant amounts of 
IFNα to protect from viral infection (Di et al., 2009; Uematsu et al., 
2005).
1.3.6  Negative Regulation TLR signalling.
TLR signalling must be appropriately attenuated to prevent tissue 
damage. Negative regulators operate at all levels of TLR signalling 
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and include  splice  variants  of  adaptor  proteins,  ubiquitin  ligases, 
deubiquitinases, transcriptional regulators and micro RNAs . Soluble 
forms  of  TLR  receptors  can  compete  with  receptors  for  ligand 
binding  to  dampen  immune  responses  .  The  TIR-TIR  interaction 
between receptors and adaptors is disrupted by proteins such as 
MyD88s (Burns  et al.,   2003 , ST2  and SIGGR . The negative adaptor 
SARM  can  interfere  with  both  TRIF  and  MyD88  pathways,  while 
MyD88 and MAL have been shown to regulate TRIF signalling to IRF 
proteins  . Downstream of the receptor SOCS-2 and SHP-1 suppress 
IRAK  signalling,  while  SOCS-2  additionally  targets  MAL  for 
degradation . ATF3 prevents the TLR induction of IL-6 and IL-12p40 
by regulating transcription factor activation . NFκB importantly leads 
to  the  induction  of  several  inhibitory  proteins,  to  form  negative 
feedback loops such as IκB and A20 .
 A20 is a potent negative regulator of NFκB signalling . It is a dual 
function enzyme, as it  can act as deubiquinating enzyme and E3 
ligase. Much of the knowledge on A20 has come from A20 knockout 
mice which display systemic inflammation and premature lethality. 
In TNFα signalling, RIP-1 is an important A20 target, while in IL-1R 
and TLR signalling, TRAF6 and IRAK1 are targets . It interacts with 
several proteins to form A20 ubiquitin editing complex composed of 
TAX1BP1, ITCH and RNF11. A20 also has non catalytic roles; as it 
can  prevent  the  interaction  of  E2  and  E3  enzymes  to  prevent 
ubiquination  .  A20  binding  to  polyubiquitin  chains  on  NEMO can 
block TAK-1 activation of IKK. This interaction may be promoted by 
ABIN1 .  Under  In vitro conditions unanchored K63 pUB chains can 
also promote the A20-NEMO interaction . Interestingly IKK proteins 
can regulate the assembly of  the A20 editing complex.  IKKα can 
phosphorylate TAX1BP1 to promote the assembly of A20 complex 
and its interaction with TRAF2/6 whilst IKKβ phosphorylation of A20 
increases its inhibitory activity .
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1.9 MAPK
Engagement of TLRs not only leads to the activation of NFκB but 
also to MAPK proteins. The MAPKs can in turn activate numerous 
proteins and transcription factors to regulate the immune response. 
They are involved in all phases of immune response from initiation 
of  innate  and  adaptive  responses  and  regulating  cell  death  of 
immune cells( Cargnello and Roux, 2011;. 
MAPK signalling operates in a three tiered mechanism where MAPK 
kinase kinases (MAPKKK) phosphorylate and activate MAPK kinases 
(MAPKK)  which  then  phosphorylate  MAPK.  MAPK  require  dual 
phosphorylation  on  conserved  tripeptide  motifs  (Thr-X-Tyr)  to  be 
activated and are distinguished into three main families dependent 
on  their  specific  residues  within  this  region;  Extracellular  signal 
regulated protein kinases (ERK) Thr-Glu-Tyr (also known as p42/44), 
p38 Thr-Pro-Tyr and c-JUN NH2-terminal kinases (JNK) Thr-Gly-Tyr. 
Recently  a fourth  family  have been recognised,  the ERK5 family. 
Dual-specificity phosphotases (DUSPs) regulate MAPK by reversing 
this dual phosphorylation, and hence have important role in immune 
regulation ; Marshal, C.J., 1994). 
A  diverse  repertoire  of  extracellular  cues  induce  the  activity  of 
MAPK, however different stimuli influence the different families with 
varying degrees. For the ERK family the main extracellular cues are 
growth promoting mitogenic  stimuli.  JNK and p38,  which are also 
classed the stress activated kinases (SAPK), are mainly activated by 
stresses  such  as  osmotic  shock,  hypoxia,  heat  shock  and  UV 
radiation and by proinflammatory signals including LPS, IL-1β, TGF-β 
and TNF-α MAPK mainly regulate inflammatory responses by directly 
or indirectly targeting transcription factor activity, regulating mRNA 
stability and also protein maturation (Cargnello and Roux 2011; Fan 
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et  al., 2005;  Guhaniyogi  and  Brewer  2001;.  MAPK  signalling 
integrates  into  several  different  networks  to  regulate  cell  death, 
proliferation  and  differentiation,  orchestrating  a  dynamic  flexible 
signalling system, that can tailor cellular responses appropriately in 
response to multiple signals
1.9.1 JNK
The  JNK  family  of  MAPK  are  involved  in  the  regulation  of  cell 
proliferation and apoptosis. There are three known isoforms, JNK 1-3 
of which JNK1 and JNK2 are widely expressed, while JNK3 expression 
is restricted to neuronal tissue, testis and cardiac myocytes. Several 
forms of stress have been shown to activate JNK signalling including 
heat  shock,  UV irradiation,  cytokines,  DNA damaging agents  and 
oxidative stress . While numerous MAPKKK have been implicated in 
JNK  activation,  such  as  Mekk1-4,  MLK  1-3,  TAK1  and  ASK1,  JNK 
activation  converges  at  the  level  of  MAPKK  specifically  on  two 
MAPKK- MKK4 and MKK7 (Bogoyevitch   et al.,   2010 ;  Cargnello and 
Roux, 2011; Derijard  et al., 1995; Lin  et al., 1995; Tournier  et al., 
1999; Weston and Davis, 2002). Tak1 is essential for JNK activation 
in response to inflammatory signals such as IL-1β, TNFα, TGF-β and 
TLR signalling . 
JNK  mediates  it  effects  primarily  through  the  activation  of 
transcription factors, it has been shown to target p53, ATF2, ELK-1, 
stat3 and c-jun (Bogoyevitch et al., 2010; Gupta et al., 1995; Raman 
et al., 2007; Whitmarch et al., 1995). A major target of JNK signalling 
is the AP-1 complex . AP-1 is a dimeric protein complex composed of 
homo  and  heterodimers  of  fos,  jun  and  ATF-2  family  members, 
exerting  its  action  by  binding  TRE  elements  in  the  promoter  of 
target genes. The composition of the AP-1 complex determines its 
targets and its action. AP-1 is essential for cell differentiation and 
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proliferation  and  regulates  many  inflammatory  genes  including 
genes encoding cytokines, chemokines,and MCP-1 . c-jun is the best 
characterised member of the AP-1 complex. It can form homodimers 
or  heterodimers  with  c-fos.  JNK  can  bind  c-jun  directly, 
phosphorylating  and  activating  it  (Alder  et  al., 1992;  Hibi  et  al., 
1993; Pulverer  et al., 1991). Many of the genes regulated by c-jun 
proteins are involved in cell  proliferation and differentiation.  Mice 
depleted of c-jun are embryonic lethal while fibroblasts from c-jun -/- 
mice have defective cell cycle progression resulting from decreased 
expression of cyclin D and increased expression of p53 and p21 .  
JNK  signalling  is  indispensible  for  induction  of  the  intrinsic  and 
extrinsic apoptopic pathways . The conflicting critical role of JNK in 
cell survival and cell death may be due to the differential outcome 
of transient and sustained JNK expression, as well as cell type and 
stimulus  specific  activity.  Transient  JNK  expression  is  associated 
with cell proliferation and survival while sustained activation of JNK 
is associated with apoptosis (Javelaud and Besancon, 2001; Kamata 
et al., 2005; Tang et al., 2001). 
JNK  signalling  is  implicated  in  the  intrinsic  apoptosis  pathway. 
Primary  fibroblasts  isolated  from  JNK1/2-/-  and  MKK4/7  -/-  mice 
displayed severe defects in apoptosis mediated by UV irradiation, 
metyl  methanesulfate  and  anisoMYCin.  This  resistance  correlates 
with  a  failure  to  release  cytochrome  C  from  the  mitochondria. 
However these cells were still vulnerable to Fas mediated apoptosis. 
JNK can target transcription such AP-1 ATF2, RXRα, RARα and p53 to 
modulate  the  expression  of  pro  and  anti  apoptopic  genes.  In 
addition it has been implicated in the regulation of  Bax, Bak and Bid 
proteins which are central to mitochondria mediated cytochrome C 
release (Deng  et al., 2003; Lei  et al., 2002; Tournier  et al., 2001; 
Tsuruta et al., 2004). 
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TNFα  signalling  can  lead  to  the  induction  of  NFκB  and  thus 
proinflammatory and prosurvival response. But it can also lead to 
the DISC formation and the induction of caspase cascade, resulting 
in apoptosis. NFκB induction is the default signalling pathway and 
must be overcome before apoptosis can proceed (De Smaele et al., 
2001; Tang et al., 2001). JNK antagonises the prosurvival effects of 
NFκB  by  targetting  the  NFκB  dependent  protein  c-FLIP  which 
functions to prevent the interaction between caspase 8 and FADD 
and thus prevent DISC formation. Activation of JNK inactivates c-FLIP 
indirectly  through  the  phosphorylation  of  the  E3  ligase  ITCH. 
Phosphorylated  ITCH  can  ubiquinate  cFLIPl  targeting  it  for 
degradation, allowing apoptosis to proceed. ITCH deficient mice are 
resistant to TNFα induced acute liver  failure (Chang  et al., 2006; 
Deng et al., 2003). 
MyD88 has been shown to negatively regulate TLR3 induced IFN-β 
production. It can inhibit the IKKβ kinase preventing phosphorylation 
of  IRF3.  In  human  corneal  epithelial  cells,  loss  of  MyD88 
exacerbated  TLR3  induced  inflammatory  responses  in  a  JNK 
dependent means . Mal has also been shown to inhibit TLR3 induced 
JNK. Mal deficiency boosted IL-6 production in response to PolyI:C .
1.9.2 P38 
 There are four isoforms of p38; p38α, p38β, p38gamma, p38delta, 
each  encoded  by  a  separate  gene.  Upstream  signalling  of  p38 
converges on MKK3 and MKK6 which are specific to the p38 family 
(Cuadrado and Nebrda, 2010). 
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P38 kinases play important roles in cytokine signalling. They have a 
dual function acting as downstream mediators in cytokine signalling 
pathways and also are involved in the post translational production 
of certain cytokines. P38 upregulates cytokine production by directly 
phosphorylating  transcription  factors  and  indirectly  through 
downstream  kinases.  They  also  regulate  mRNA  stabitility  and 
translation  through  phosphorylation  of  3’  UTR 
adenylate/uridylate-rich elements(ARE) in target proteins (Schieven, 
2005). p38 activation of MK2 is essential for the induction of TNFα. 
Mice deficient in MK2 have increased stress resistance and could 
survive LPS induced shock. It  was shown that in response to LPS 
that TNFα levels in vivo in serum and in vitro in splenocytes were 
reduced when MK2 was knocked out. However the mRNA levels of 
the TNfα were not affected. The effect of MK2 knockout is exerted at 
the  posttranscriptional  level.  3’  UTR  ARE  regions  of  mRNA 
transcripts  are  targeted  by  p38-activated  MK2  (Kotlyarov  et  al., 
1999). p38 inhibitors in WT mice could block the production of TNFα, 
however  these  inhibitors  had  no  affect  on  TNFα  mutants  with 
detective  ARE  regions.  The  p38-MK2-ARE  action  is  targeted  and 
inhibited by Il-10, preventing TNFα production (Kontoyiannis  et al., 
2001).  Other  ARE-containing  mRNAs  targeted  by  p38  pathway 
include  COX-2,  IL-1β,  IL-6,  IL-8,  MIP-1,  CXCL-10,  c-fos  and  VEGF 
(Khabar, 2010).
p38  signalling  to  CREB  is  important  for  the  regulation  of  CREB 
responsive genes such as TNFα, IL-2, IL-6, IL-10 and COX-2 (Avni et 
al., 2010;  Eliopoulous  et  al., 2002;  O’  Donell  and  Taffet,  2002; 
Platzer  et al., 1999; Shaywitz and Greenberg, 1999; Roach  et al., 
2005; Wiggen et al., 2002). LPS signalling has been shown to induce 
phosphorylation  of  CREB  in  p38  manner.  Interesting  this  is 
dependent on MAL signalling, while the E3 ligase Pellino and TRAF6 
are  also  involved.  Phosphorylated  p38  in  turn  activates  MSK1/2 
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which  can  phosphorylate  CREB  (Caivono  and  Cohen,  2000; 
Eliopoulos et al., 2002; Mellet et al., 2011). 
1.9.3 ERK
The canonical pathway of ERK activation is through the Ras-Raf-ERK 
pathway which is activated in response to growth factors (Kolch, 
2005). However cytokine and TLR receptors activate MAPKs 
primarily via the MAP3K TPL-2 (Symons and Ley, 2006). ERK 
activation in response to LPS and IL-1β leads to the phosphorylation 
of ELK-1 and C/EBP transcription factors. C/EBP proteins are 
important for the upregulation of several proinflammatory 
mediators, G-CSF, IL-6/8/1, TNFα and iNOS. ELK-1 phosphorylation 
leads to expression of c-fos which as part of AP-1 complex leads to 
upregulation of cytokines and MMP proteins (Cargnello and Roux, 
2011). ELK-1 may also have anti-inflammatory roles as ELK-1 
signalling has been shown to contribute to the NFκB induction of 
MCPIP, a protein that negatively regulate the stability of several 
inflammatory transcripts such as IL-1β and IL-12p40 (Kasza et al., 
2011). 
In an immunological sense it seems the majority of ERK activation is 
through  the  IKK-TPL2  axis  (Figure  1.2)  (Gantke  et  al., 2012). 
Knockout of the MAPKKK TPL2 showed that TPL2 is essential for the 
LPS activation of MEK1/2 and ERK1/2 but is dispensible for p38 and 
JNK  activation.  TPL2  knockout  mice  are  resistant  to  LPS  induced 
endotoxic shock (Dumitru  et al., 2000).  A Yeast 2 hybrid screeen 
identified p105 as a TPL2 interacting partner (Belich  et al., 1999). 
While only a small pool of p105 is associated with TPL2, the majority 
of cellular TPL2 is coupled to p105 ((Dumitru  et al., 2000; Lang et 
al., 2004; Yang et al., 2004). TPL2 does not regulate the function of 
p105  as  TPL2-deficient  cells,  when  treated  with  LPS,  retain  the 
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ability to activate p105. However, P105 was found to exert strong 
control of TPL2, regulating its stability and activity. In p105-deficient 
macrophages,  TPL2 levels  are near depleted and there is no LPS 
induced activation  of  ERK (Beinke  et  al., 2005;  Waterfield  et  al., 
2003). The interaction between TPL2 and p105 occurs at two points, 
the first between the C terminus of TPL2 and the ankyrin repeat of 
p105, and the second between the kinase domain of TPL2 and the 
death domain of p105. This second interaction blocks the activity of 
TPL2s kinase domain and prevents MEK1/2 activation (Beinke et al., 
2005).  In  macrophages  this  interaction  is  regulated  by  the  IKK 
proteins. LPS stimulation leads to the phosphorylation of S927 and 
S932 in the PEST region of p105 by IKK. SCFβtrcp can then target 
p105 with K48 pUB chains and induce its partial degradation to the 
p50 subunit. This proteolysis of p105 is essential for LPS activation 
of TPL2, as it releases TPL2 and removes inhibitory effects of p105 
(Beinke  et  al., 2004;  Lange  et  al., 2003;  Salmeron  et  al., 2001; 
Waterfield  et  al., 2004).  ABIN2 is  also  complexed  with  TPL2  and 
p105 however its role in the complex is unclear. ABIN2-/- mice have 
comparable  NFκB  activation  compare  to  WT.  However  the  TPL2 
activation of  ERK is  reduced.  ABIN2,  like p105,  is  not  thought  to 
directly  regulate  the  catalytic  activity  of  TPL2  but  controls  its 
stability (Papoutsopoulou et al., 2006). 
Independent of p105 and ABIN2, TPL2 is regulated by LPS induced 
phosphorylation on several residues (Dumitru et al., 2000; Yang et 
al., 2004). The phosphorylation state of TPL2 has been shown to be 
dependent  on  the  nutrient  content  of  the  environment.  In  the 
absence of the amino acid arginine, TPL2 associates with PP2A and 
is dephosphorylated, preventing MEK1/2 activation. 
The main outcome of TPL2 knockout is a drastic decrease in LPS 
induced  TNFα  production  in  macrophages.  It  has  since  been 
revealed that the TPL2-ERK axis can target TNFα at transcriptional, 
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posttranscriptional  and  protein  levels.  TPL2/ERK  can  target  the 
transcription  of  TNFα  mRNA  as  well  as  its  translation  through 
phosphorylation of  its 3’ UTR ARE regions (Dumitru  et al., 2000). 
TNFα  is  produced  in  a  pre-TNF  form  which  is  a  type  II 
transmembrane protein and must be cleaved by the enzyme TACE 
to  form  the  soluble  form.  Inhibition  of  ERK  in  macrophages 
significantly decreases the levels of soluble TNFα. This is explained 
by  the  phosphorlation  of  TACE  on  thr735  by  LPS  induced  ERK 
(Rousseau  et al., 2008).  TPL2 deficiency also resulted in reduced 
IL-10 and IL-1β mRNA levels ,  while IL-12 and IFN-β mRNA levels 
were increased. The regulation of IL-12 by TPL-2 is a combination of 
direct  regulation  of  Il-12  and  indirect  regulation  through  IL-10 
regulation.  Conversely  the  regulation  of  IFN-β  was  completely 
independent of IL-10, but involves the induction expression of the 
transcription  factor  c-fos  (Kaiser  et  al., 2009).  Loss  of  TPL2  in 
addition affects macrophage production of PGE2.TPL2 is required for 
ERK stimulation  of  MSK1,  which  can  activation  CREB to  regulate 
COX-2  transcription.  COX-2  then  regulates  PGE2  production 
(Eliopoulos  et  al., 2002).  Despite  the  pro-  and  anti-inflammatory 
effects, TPL2 is considered to be proinflammatory protein as it  is 
required for clearance of Listeria monocytogenis bacteria (Mielke et 
al., 2009).
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 Figure 1.2: Tpl-2 Signalling pathway. Under Basal conditions Tpl2 associates with 
p105 and ABIN2. TLR4 signalling results in IKKβ activation, which can 
phosphorylate p105 leading to its processing to p50 and release of Tpl2. Tpl2 can 
then target the p42/44 pathway by activating MEK. P42/44 subsequently can 
activate and induce transcription factors with both pro- and anti-inflammatory 
activity. It also plays a role in the post transcriptional activation of TNF-α by 
targeting the enzyme TACE. Taken and modified from Vougioukalaki et al., 2011.
1.10 ECSIT
 
Evolutionary  Conserved  signalling  intermediate  in  toll  (ECSIT) 
protein  was  first  discovered  in  1999  by  Kopp  et  al., In  a  bid  to 
understand  the  signalling  mechanisms  linking  TRAF6  to  IKK 
activation  they  preformed  a  yeast  two  hybrid  screen  of  TRAF6 
against mouse liver library. ECSIT was discovered as 1.2kDa cDNA 
transcript  whose  encoded  protein  interacted  with  TRAF6.  Further 
northern blot analysis revealed 3 alternatively spliced forms of the 
protein,  named ECSIT 1/2/3.  ECSIT displayed no homology to any 
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known proteins and had no known protein domains. However the 
protein was highly conserved across Drosophila and C. elegans and 
thus was termed ECSIT.   The initial  functional  characterisation of 
ECSIT found that ECSIT specifically interacted with TRAF6 and not 
TRAF2 or TRAF5 and its overexpression increased NFκB in a dose 
dependent manner in the presence of TLR4, IRAK1 and TRAF6. A 
dominant  negative  version  of  ECSIT  blocked  NFκB  activation  in 
presence of  IRAK1 but  not  RIP1 indicating ECSIT was specific  for 
TLR4  signalling  and  not  TNFR  signalling.  Furthermore  ECSIT  was 
found  to  interact  with  MEKK1  and  lead  to  increased  MEKK1 
processing into the proposed active 80kDa isoform. Based on these 
finding it was postulated that ECSIT formed the critical link between 
TRAF6 and MEKK1 leading to NFκB and AP-1 activation.  However 
this theory is now widely disputed as MEKK1 knockout mice don’t 
display defects in NFκB signalling (Zhang et al., 2003). 
ECSIT  knockout  mice  display  embryonic  lethality  and die  on day 
E7.5. Interestingly analysis of these embryos revealed a phenotype 
that mimicked that of BMPR1a knockout mice (Xiao  et al., 2003). 
BmpR1a is the receptor for BMP4 a member of TGFβ superfamily. It 
signals  via  SMAD  proteins  and  is  critical  during  embryonic 
development with roles in cell proliferation, survival and formation 
of  the  mesoderm  (Winnier  et  al., 1995).  ECSIT  null  mutants 
displayed  decreased  cell  proliferation,  altered  epiblast  patterning 
and impaired mesoderm. ECSIT was found to constitutively interact 
with SMAD4 and to interact with SMAD1 in a BMP inducible manner. 
A SMAD4/1/ECSIT complex was found to bind the promoter of Tlx2, a 
BMP inducible gene leading to TLx2 expression. ECSIT ShRNA was 
used  to  knockdown  ECSIT  levels  and  was  found  to  abolish  Tlx2 
activity and LPS induced NFκB activation (Xiao et al., 2003). 
Since  these  initial  discoveries  ECSIT  has  slowly  become a  prime 
focus in innate signalling, with several groups publishing on ECSIT in 
xli
recent years. ECSIT localises to the mitochondria via a N-terminal 
target  sequence.  It  can  interact  with  the  chaperone  protein 
NDUFUFA1 in  500 and 850kDA complexes and is  involved in  the 
assembly and function of Complex1 in the mitochondrial respiratory 
chain (Vogel  et al., 2007).  The relevance of ECSITs mitochondrial 
localisation  in  the  context  of  innate  immune  signalling  was 
established by the work  of  West  et  al., 2012.  Bacterial  killing  in 
phagocytes is mediated by the generation of  ROS in phagocytes. 
This  has  always  been  considered  due  to  production  of  ROS  by 
NADPH  oxidase.  However  recent  studies  looking  at  mouse 
macrophage  killing  of  bacteria  has  implicated  mROS  to  be 
important, requiring signalling from bacterial sensing TLRs. West et 
al., 2012   demonstrated  that  TRAF6  and  ECSIT  are  required  for 
macrophage killing of  intracellular  bacteria. Upon TLR 1,  2 and 4 
signalling  in  macrophages,  mitochondria  are  recruited  to  the 
phagosome, while TRAF6 translocates to the mitochondria. TRAF6 
can bind to and ubiquitinate  ECSIT resulting in  an enrichment of 
ECSIT to the mitochondrial periphery and a concomitant increase in 
both  mitochondrial  and  cellular  production  of  ROS.  Macrophages 
deficient in TRAF6 and ECSIT fail to clear infection.  Thus proving in 
a physiological context the importance of mECSIT in TLR signalling.
 
ECSIT role is not confined to TLR signalling and has recently been 
shown to extend to RLR signalling (Kondo et al., 2012). As with the 
original discovery of ECSIT by Kopp  et al., ECSITs role in RLR was 
eluded from a yeast two hybrid screen. In this case TRIM59, a newly 
discovered ER-localised TRIM protein, was used as bait. The authors 
investigated the role of ECSIT and TRIM59 in RLR signalling as the 
common  mitochondrial  location  of  MAVS  and  ECSIT  and  their 
overlapping signalling intermediates raised the possibility that they 
interacted.  Indeed  this  was  confirmed  by  coimmunoprecipitation 
and confocal studies which showed that ECSIT interacts with MAVS 
and enhances MAVS mediated IFN-β promoter  activation.  TRIM59 
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was  found  to  negatively  affect  the  MAVS  induced  transcriptional 
activation  in  the  NFκB  responsive  element  and  IFN-β  and  IRSE 
promoters.  It  was  postulated  that  TRIM59  may  negatively  affect 
MAVS  signalling  via  ECSIT.  However  TRIM59  fails  to  ubiquinate 
ECSIT. Although not conclusive these results implicate ECSIT in RLR 
signalling.  TRIM59  knockout  mice  once  generated  will  further 
establish ECSITs role.
1.12 Aims of the project.
The main objectives of this project were:
• Determine the functional role of hECSIT in MAPK signalling and 
its ability to modulate activation of  the transcription factors 
ELK-1 and Ap-1.
• To  screen  for  ECSIT  interacting  partners  by  an  unbiased 
proteomic approach.
• To  identify  a  possible  mechanism  of  action  underlying  the 
regulatory effects of hECSIT in MAPK signalling.
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2. Materials and Methods.
2.1 Materials
2.1.1 Reagents                                  
Supplier
Agar Sigma
Agarose    Promega
Agarose, low melting point Sigma
Ampicillin Sigma
Antibodies (monoclonal) against human-
β-Actin  
Sigma
FLAG M2                Sigma
HA-Tag (6E2) Cell 
Signalling 
MYC-Tag (9B11)              Cell 
Signalling 
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Antibodies (polyclonal) against human-
                         ECSIT/SITPEC 
MyBioScource.com
Ampholytes 
Amersham Bioscience
Acetic Acid Sigma
Acetronitrile 
Amersham Bioscience
Ammonium Bicarbonate              Sigma
APS Sigma
Bovine serum albumin Sigma
Bradford reagent dye Bio-Rad
Bromophenol blue Sigma
Chaps  
Sigma
Chloroform 
Sigma
Coelenterazine Insight 
Biotech.
Coomassie  Blue 
Sigma
Cover fluid Amersham 
Bioscience
DEPC-treated water Ambion
DMEM  
Invitrogen
DMSO Sigma
dNTPs Promega
DTT Sigma
E.coli - TOP 10 competent cells
Invitrogen
EDTA Sigma
xlv
Ethanol 
Sigma
FBS Invitrogen
Formalin Sigma
Formic Acid Fluka
Glycerol Sigma
Glycine              Sigma
HEPES                  Sigma
High speed plasmid midi kit Qiagen
Hydrochloric acid Merck
Igepal 
Sigma
IL-1β (human) RandD 
Systems
Iodoacetamide                Sigma
IPG strips  Amersham 
Bioscience
IRDye  800CW  Goat  Anti-Rabbit 
Licor Biosciences
IRDye  680  Donkey  Anti-Mouse 
Licor Biosciences
Isopropanol Sigma
L-glutamine Invitrogen
Lipofectamine 2000
Invitrogen
Lipopolysaccharide Alexis
Luciferase substrate Promega
Magnesium Chloride Sigma
β-Mercaptoethanol              Sigma
Methanol BDH
Microlon 96-well plates Greiner
Nitrocellulose  
Schleicher and Schuell
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OptiMEM 
Invitrogen
PBS Oxoid
pcDNA 3.1/Zeo Invitrogen
Penicillin / StreptoMYCin / Glutamine
Invitrogen
PMSF Sigma
Poly (I:C) Sigma 
Polybrene 
Sigma
Ponceau Sigma
Potassium ferricyanide Sigma
Prestained molecular weight marker (See Blue Plus)
Invitrogen
Protein A/G-agarose Santa 
Cruz
Protogel National Diagnostics
Puromycin 
Sigma
RNase Zap Ambion
RPMI           Invitrogen
SDS Sigma
siRNA hECSIT specific  
Ambion
siRNA Lamin a/c Ambion
Skim milk powder Sigma
Silver nitrate Sigma
Sodium chloride (NaCl) Sigma
Sodium hydroxide (NaOH) Sigma
Sodium orthovanadate (Na3VO4) Sigma
Sodium nitrate               Sigma
Sodium Phosphate Sigma
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Sodium Potassium Carbonate Sigma
Sodium thiosulphate Sigma
Sulphuric acid Sigma
TEMED              Sigma
TMB Sigma
Tissue culture ware Greiner
TK Renilla Promega
TNF-α RandD 
Systems
Thiourea 
Sigma
Trifluroacetic acid              Sigma
Tris-base Sigma
Tris-HCl Sigma
Triton-X Sigma
Trypsin/EDTA  
Invitrogen
Tween-20 Sigma
Ultrapure  Protogel 
National Diagnostics
Urea Sigma
Whatmann paper                                   
AGB 
Cell Lines given as gifts:
• HEK293 and HEK293 stably expressing TLR4 - Prof. Douglas T. 
Golenbock (The University of Massachusetts Medical School, 
Worcestor, Massachusetts 01605, USA).
• A549  cells-  Dr  Shirley  O’  Dea  (Epithelial  Immunbiology 
Laboratory, NUI Maynooth, Co. Kildare). 
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• U373 cells- Dr Sinead Miggen (Immune signalling Laboratory, 
NUI Maynooth, Co. Kildare).
2.2 Methods
2.2.1 Cell Culture
2.2.1.1 Adherent Cell Lines
Human embryonic kidney (HEK) 293 cells, HEK 293 cells that stably 
express  TLR4  receptor  (HEK  293  TLR4  cells),  human  U373 
astrocytoma cells  stably  transfected with  CD14 (U373-CD14)  and 
carcinomic  human  alveolar  basal  epithelial  A549  cells  were 
maintained  in  Dulbecco’s  Modified  Eagle  Medium (DMEM),  which 
was supplemented with 10% (v/v) foetal bovine serum (FBS), 100 
μg/ml penicillin and 100 µg/ml streptoMYCin. Cells were maintained 
in a 37ºC humidified atmosphere with 5% CO2. Cells were passaged 
every  2  to  3  days  using  1%  (w/v) 
Trypsin/ethylenediaminetetraacetic  acid  (EDTA)  solution  in 
phosphate-buffered saline (PBS). The neoMYCin analog G418 (500 
µg/ml) was used to select for the stably transfected TLR cell lines 
and maintenance of CD14 expression.
2.2.2 Propagation of DNA
2.2.2.1 Rapid transformation of competent E. coli cells
TOP10 chemically competent E. coli cells were used for propagation 
of plasmids. Plasmid (100-400ng) was added to 5 µl of TOP10 cells. 
DNA and the cells were mixed gently with a pipette and incubated 
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on ice for 30 min. The plasmids were allowed to enter the bacterial 
cells by heat shocking the mixture at 42ºC for 60 seconds. The cell 
membrane becomes permeable to allow easy entry of the plasmid 
and  cooling  on  ice  for  2  min  reverses  the  membrane  to  an 
impermeable state. The transformed cells were then incubated in 1 
ml  Luria  Bertoni  (LB) broth  (1% (w/v) tryptone,  0.5% (w/v)  yeast 
extract, 85 mM NaCl) at 37ºC on a shaker at 220 rpm for 2-4hr. 
Transformed  cells  were  pelleted  by  centrifuging  at  1000rpm  for 
2min at 4 ºC and then resuspended in 100µl of LB. An aliquot (50µl) 
of mix  was plated out on LB agar plates (LB broth with 1.5% (w/v) 
agar)  containing  100  μg/ml  ampicillin.  Plates  were  inverted  and 
incubated overnight at 37 ºC. Plates were then stored at 4 ºC for up 
to four weeks.
2.2.2.2 Large scale preparation of DNA from E. coli
A starter culture of LB broth (2 ml) containing ampicillin (50 μg/ml) 
was  inoculated  with  a  single  transformed  E.  coli colony  and 
incubated at 37ºC with shaking at 220 rpm for 6-8 h. This was then 
added  to  a  larger  volume  of  LB  broth  (100  ml)  containing  the 
relevant antibiotic and incubated at 37ºC overnight shaking at 220 
rpm. Large plasmid preparations were made using the Qiagen high 
speed plasmid midi kit. The bacterial cells were centrifuged at 3000 
rpm for 40 min and the supernatant was discarded and the plasmid 
DNA was  extracted  as  outlined  in  the  manufacturer’s  handbook. 
DNA  was  quantified  by  spectrophotometry  (  Nanodrop;   Thermo 
Scientific).
2.2.3 Luciferase assay.
l
2.2.3.1 Transfection of HEK293 cells for luciferase reporter 
assay
HEK  293  TLR4  cells  were  seeded  at  1.8x10^5  cells/ml  (200  μl 
DMEM/well)  in  96-well  plates  and  allowed  to  adhere  for  24  h  to 
approximately  70%  confluency.  Cells  were  transfected  using 
Lipofectamine  2000.  For  each  well  to  be  transfected,  25  µl  of 
OptiMEM (Invitrogen)  was  mixed with  the  DNA.  DNA mixes  were 
made  up  for  the  appropriate  luciferase  construct  as  outlined  in 
section 2.2.3.2. Lipofectamine 2000 (0.4 μl) was diluted in OptiMEM 
(25 µl) per sample and the reaction was mixed gently and left at 
room  temperature  for  5  min.  After  the  incubation,  the 
Lipofectamine/OptiMEM  solution  was  added  to  the  DNA/OptiMEM 
mix  (total  volume  50  µl  per  well  to  be  transfected)  and  the 
combined  reaction  was  mixed  gently  and  incubated  at  room 
temperature for 20 min. The transfection mixture was then added to 
each well and mixed gently by tapping the side of the plate. Each 
sample  was  transfected  in  triplicate.  24  h  after  transfection  the 
supernatants were removed, cell lysates were generated and used 
to measure luciferase activity.
2.2.3.2 Luciferase Assays
24 h post-transfection (as described in section 2.2.3.1), the medium 
was  removed  from  the  cells  and  reporter  lysis  buffer  (100  µl, 
Promega) was added to each well using a multi-channel pipette. The 
plate was then wrapped in aluminium foil and placed on a rocker for 
30 min at  room temperature  before  being placed at  -80ºC for  a 
minimum of 1 h. After thawing at room temperature, aliquots (40 µl) 
of  each  were  assayed  for  firefly  luciferase  activity  using  firefly 
luciferase  substrate  (40  µl,  Promega),  while  Renilla  luciferase 
activity  was  assayed  using  coelenterazine  (0.1  µg/ml  in  PBS). 
Luminescence  was  monitored  with  a  Glomax  microplate 
luminometer (Promega).
2.2.3.2.1 NF-ĸB Assay
li
To measure activation of the NFκB pathway, cells were transfected 
with  NFκB  -regulated  firefly  luciferase  reporter  plasmid  (80  ng), 
constitutively  expressed  Renilla-luciferase  reporter  construct 
phRL-TK  (20  ng)  and  varying  amounts  of  expression  constructs 
(detailed  in  figure  legends).  The  total  amount  of  DNA  was 
maintained at 200 or 250 ng using pcDNA3.1.
2.2.3.2.2 AP-1 Assay
To  measure  the  activation  of  Ap-1,  cells  were  transfected 
AP-1-regulated firefly luciferase (80ng), phRL-TK (20ng) and varying 
amounts of expression constructs (detailed in figure legends). The 
total DNA concentration was maintained at 230 or 250 ng using the 
appropriate empty vector.
2.2.3.2.3 ELK-1 Assay
To  measure  the  activation  of  ELK-1,  cells  were  transfected  with 
pFR-Luc (60 ng), the trans-activator plasmid pFA-ELK-1 (ELK-1 fused 
downstream of the yeast Gal4 DNA binding domain, (3ng), phRL-TK 
(20 ng) and varying amounts of expression constructs (detailed in 
figure legends). The total DNA concentration was maintained at 230 
ng using the appropriate empty vector.
2.2.4 SDS PAGE Electrophoresis and Western Blotting
2.2.4.1 Transfection of cells for Western Blot analysis
HEK293 or U373 cells were seeded at 2 x 10^5 cells/ml in 6-well 
plates  (2.5  ml  DMEM/well).  Cells  were  grown  for  24  h  to 
approximately 70% confluency. For each well of a 6-well plate to be 
transfected,  DNA  (amount  depending  on  individual  assays  as 
outlined  in  relevant  sections)  was  diluted  in  OptiMEM  (250  µl) 
(Invitrogen) and mixed gently. Lipofectamine 2000 (4 µl) was then 
diluted in  OptiMEM (250 µl)  and incubated at room temperature. 
After  5  min  incubation,  the  diluted  DNA was  combined  with  the 
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diluted Lipofectamine 2000, mixed gently, and incubated at room 
temperature for 20 min. 500µl of DNA-Lipofectamine mixture was 
added to each well. After 24hrs cells were treated with appropiate 
ligands for various times. Samples were then analysed by SDS-Gel 
Electrophoresis and Western Blotting.
2.2.4.2 Transfection of cells with siRNA for Western Blot 
Anaylsis.
Lamin a/c siRNA and siRNA targeting hECSIT was purchased from 
Ambion Inc. (target sequence : 5’ GGTTCCTTTGCCCAAAGACTT 3’).
U373 cells were seeded at 2 x 10^5 cells/ml in a 6-well plates (2.5 
ml DMEM/well).  Cells  were grown for 24 h to approximately  70% 
confluency.  10nM  of  hECSIT-specific  siRNA  or  Lamin  a/c  control 
siRNA, which has no significant homology to any known human gene 
sequences,  were  diluted  in  OptiMEM  (250  μl)  mixed  gently  and 
incubated for 5min.  Lipofectamine 2000 (4 μl) was also diluted in 
250μl of OptiMEM per sample, the reaction was mixed gently and 
left  at  room  temperature  for  5  min.  After  the  incubation,  the 
Lipofectamine/OptiMEM solution was added to the OptiMEM-siRNA 
mix  (total  volume  500  µl  per  well  to  be  transfected)  and  the 
combined  reaction  mixed  gently  and  incubated  at  room 
temperature for further 20 min. 500 µl sample was then added to 
each well  and mixed gently by rocking the plate back and forth. 
Cells were incubated for 48 h prior to treatment and harvesting.
2.2.4.3 Harvesting of Cells for Western Blotting
U373 cells  or  HEK293 cells  seeded at  a density  of  2x10^5/ml  in 
6-well  plates.   Cells  were  grown  for  24  h  to  approximately  80% 
confluency.  The next day, cells were stimulated with TLR ligands for 
1  h-3  h.  To  prevent  induction  of  stress  activated  MAPKs  during 
harvesting,  harvesting was done rapidly at room temperature. All 
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media was removed from 6 well plate, cells were washed with room 
temperature  PBS and then 100-150µl  of  cell  lysis  buffer  (50 mM 
Tris-HCl, pH 7.5, containing 150 mM NaCl, 0.5% (w/v) igepal and 50 
mM  NaF,  with  1  mM  Na3VO4,  1  mM  dithiothreitol  (DTT),  1  mM 
phenylmethylsulfonyl fluoride (PMSF) and protease inhibitor mixture 
(leupeptin  (25 µg/ml),  aprotinin  (25 µg/ml),  benzamidine (1 mM), 
trypsin  inhibitor  (10  µg/ml)).  Cells  were  gently  scraped from the 
plate  and  transferred  into  pre-cooled  microcentrifgue  tubes. 
Samples were centrifuged at 15000 RPM for 15mins at 4 degrees. 
Supernatant was transferred to new microcentrifuge tubes and was 
mixed 4:1 with SDS-PAGE sample buffer (0.125 Tris-HCl pH 6.8, 20% 
(v/v) glycerol, 4% (w/v) SDS, 1.4 M β-mercaptoethanol and 0.0025% 
(w/v) bromophenol blue).  All samples in sample buffer were boiled 
for 5min and either stored at -20ºC or separated on SDS-PAGE gels.
2.2.4.4  SDS-polyacrylamide gel electophoresis (SDS-PAGE)
SDS-PAGE  was  conducted  according  to  the  method  of  Laemmli 
(Laemmli 1970), as modified by Studier (Studier 1973). Samples and 
appropriate prestained (26.6-180 kDa) protein markers were loaded 
into separate wells. Electrophoresis was performed at 80 V through 
a 5% SDS polyacrylamide stacking gel and then through a 10% SDS 
polyacrylamide resolving gel at 110 V for 1.5-3 h, depending on the 
size of the proteins being electrophoresised.
2.2.4.5  Immunoblotting
Following  separation  by  electrophoresis,  the  proteins  were 
transferred  electrophoretically  to  nitrocellulose  membranes  in  a 
Hoefer TE 70 Semiphor semi-dry transfer unit  at 110 mA for 2 h 
using  Whatmann  and  nitrocellulose  pre-soaked  in  cold  transfer 
buffer (25 mM Tris Base, 0.2 M glycine and 20% (v/v) methanol) for 
10 minutes. Following transfer, non-specific binding was blocked by 
incubating the nitrocellulose membranes at room temperature for 1 
h (or overnight) in TBS (20 mM Tris-HCl pH 7.5, containing 0.05% 
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(v/v) Tween 20 and 0.5 M NaCl) containing 5% (w/v) skimmed milk 
powder. The membranes were then washed 3 times for 4 minutes 
each in TBS prior to incubation at 4ºC overnight with the primary 
antibodies diluted in TBS containing 5% (w/v) skimmed milk powder. 
The membranes were subsequently subjected to 3 x 5 min washes 
in TBS prior to incubation with secondary antibody (1:5000 dilution) 
specific  for  the  primary  antibody  in  question  (anti-rabbit  or 
anti-mouse) in Odyssey Blocking Buffer (Licor, Bioscience) for 1 h at 
room temperature. The membranes were then washed a further 3 
times  for  4  min  each  in  TBS.  The  immunoreactive  bands  were 
detected  using  Odyssey  Infrared  Imaging  System  from  Licor 
Biosciences, according to the instructions of the manufacturer.
1º Antibody Dilution 2º Antibody*
β-Actin              1:1000 mouse
MYC 1:1000 mouse
ECSIT 1:1000 rabbit
Flag 1:500 mouse
HA 1:1000 mouse
Phospho-p38 1:500 rabbit
Phospho-p42/44                      1:1000                                         
rabbit
Phospho-p65 1:1000 rabbit
Phospho-JNK                             1:500                                           
rabbit
P38                                              1:1000 rabbit
P42/44                                        1:1000                                        
rabbit
JNK              1:1000             rabbit
* All secondary antibodies were used at a dilution of 1:5000.
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2.2.4.6 Co-ImmunoPrecipitation (CoIPs)
HEK293  TLR4  cells  were  transfected  with  Lipofectamine  2000  as 
previously  described  in  section  2.2.4.1  with  equal  amounts  of 
potentially interacting proteins. Cell extracts were generated on ice. 
Cells were first washed with pre-chilled 1 x PBS (1 ml) then lysed 
with  pre-chilled  500μl  cell  lysis  buffer  (50  mM  Tris-HCl,  pH  7.5, 
containing 150 mM NaCl, 0.5% (w/v) igepal and 50 mM NaF, with 1 
mM Na3VO4, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl 
fluoride (PMSF) and protease inhibitor mixture (leupeptin (25 µg/ml), 
aprotinin  (25  µg/ml),  benzamidine  (1  mM),  trypsin  inhibitor  (10 
µg/ml)) for 30 min on a rocker at 4ºC. Lysates were scraped into 
pre-chilled 1.5 ml microcentrifuge tubes and centrifuged at 12,000 g 
for 10 min at 4ºC. Supernatants were removed to fresh tubes (10% 
of sample was retained for whole cell lysate analysis) and incubated 
for  30  min  with  mouse  or  rabbit  immunoglobulin  (Ig)  G  (1  μg) 
(depending on the primary antibody) and Protein A/G agarose beads 
(10 μl) on a rotator at 4 ºC. Samples were centrifuged at 1000 g for 
5  min  at  4ºC  to  pellet  beads  with  non-specific  protein  and 
supernatants  were  removed  to  fresh  pre-chilled  tubes.  Samples 
were  incubated  overnight  with  primary  antibody  (2  μg).  The 
following day Protein A/G agarose beads (20-30 μl) were added to 
each sample and they were again incubated at 4ºC overnight. The 
subsequent day samples were centrifuged at 16,000 g for 1 minute 
and supernatant removed. The beads were washed with CoIP lysis 
buffer  (500 μl)  and  subjected  to  re-centrifugation.  This  step was 
repeated five times. The columns were moved to fresh tubes and 
20-40 μl of 2 x sample buffer (0.125 M Tris-HCl, pH 6.8, containing 
20% (w/v)  glycerol,  4% (w/v)  SDS,  1.4  M β-mercaptoethanol  and 
0.0025% (w/v) bromophenol blue) was added to the columns for 30 
minutes at RT. Samples were centrifuged at 16,000 g for 2 minutes, 
to  pellet  agarose  beads.  Supernatants  were  transferred  to  new 
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eppendorf tubes and subsequently boiled at 100ºC for 5-10 minutes 
and  analyzed  using  SDS  polyacrylamide  gel  electrophoresis  and 
western blotting.
2.2.5 hECSIT Lentiviral shRNA infection and generation of 
stable cell lines
2.2.5.1 Lentiviral production
HEK293 T cells were seeded at 2 x 10^5 cells/ml in 6-well plates 
(2ml  DMEM/well)  and  grown  for  24  h  to  approximately  70% 
confluency.  The cells  were  transfected as  in  section  2.2.4.1.  The 
DNA  mixture  contained  packaging  plasmid  (900  ng),  envelop 
plasmid (100 ng) and the hECSIT-shRNA or control shRNA (1 μg) for 
a total of 2 μg DNA to be transfected. shRNA hECSIT sequence was 
as follows:
ShRNA hECSIT A7
5’- 
CCGGGCCCTTTGAGTGTACAGCAAACTCGAGTTTGCTGTACACTCAAAG
GGCTTTTTG -3’
A  control  shRNA  was  also  used  in  the  transfection.  It  is  a 
non-targeting  shRNA  vector  that  will  activate  the  RNA-induced 
silencing  complex  (RISC)  and the  RNAi  pathway,  but  it  does  not 
target any human or mouse genes. The shRNA hECSIT and shRNA 
control  plasmids  were  purchased  from  Sigma.  To  remove  the 
transfection reagent, the media was changed 24 h post-transfection 
and replaced with fresh high serum (30%) growth media. The cells 
were then incubated for 24 h. The media containing lentivirus were 
harvested  ~48  h  post-transfection  and  transferred  to  a 
polypropylene tube for storage at -20°C. The media was replaced 
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with  fresh  high  serum  (30%)  growth  media  and  the  cells  were 
incubated for further 24 h. The virus was harvested one more time 
and after the final harvest the packaging cells were discarded.
2.2.5.2 Lentiviral infection
U373 cells  were seeded at  2 x  10^5 cells/ml  in  6-well  plates  (2 
ml/well  DMEM). The cells were left to recover overnight and then 
infected with 600μl of virus-containing conditioned media. Polybrene 
(8 μg/ml) was added to improve transduction efficiency. The plates 
were incubated at 37ºC. The media was removed 24 h post-infection 
and  replaced  with  fresh  growth  media  containing  puromycin  (5 
μg/ml)  to  select  for  cells  transduced  with  shRNA.  Cells   were 
cultured for 4 weeks before suppression of hECSIT expression was 
determined. These stable cell lines were then used for Western Blot 
experiments.
2.2.6 Two-Dimensional Electrophoresis (2-DE)
2.2.6.1 Transfection and Co-IP of Samples
HEK293 T cells were seeded at 2 x 10^5 cells/ml in T175cm flasks 
(20ml/flask DMEM). This was done in five replicates to be pooled 
when  harvested.  Cells  were  transfected  the  next  day  with  50µg 
hEcsit or 50µg PcDNA3.1+ per flask. To transfect DNA, 50µg of DNA 
was  added to  3mls  of  optiMEM,  while  50µl  of  lipofectamine  was 
added to 3mls of optiMEM. Both mixtures were left for 5 min and 
then  gently  mixed.  After  incubating  for  20  min,  this 
DNA-lipofectamine-optiMEM mix was carefully pipetted onto cells.
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After 24 hr the media was removed, cells were washed in 5 ml of 
ice-cold PBS, and 2 ml of NP40 lysis buffer was added. Cells were 
left on rocker for 30 min at 4ºC. Following this period, cells were 
removed from flask by gentle scraping and collected in pre-cooled 
microcentifuge  tubes.  Cell  debris  was  pelleted  by  spinning  at 
12000g for 10min at 4ºC. The supernatant was then transferred to 
new microcentrifuge tubes and 4µl/ml of anti-c- MYC antibody was 
added to samples, and left for 24 hr. 10µl of A/G beads was then 
added  per  1µg  of  antibody.  The  subsequent  day  samples  were 
added  to  chilled  spin  columns  (Cytosignal)  and  centrifuged  at 
16,000 g for 1 minute. The beads were washed with lysis buffer (as 
described  in  section  2.2.4.6)  (500  μl)  and  subject  to 
re-centrifugation. This step was repeated five times. The columns 
were moved to fresh tubes and 100µl of proteomic lysis buffer (7 M 
urea,  2M  thiourea,  65  mM 
(3-[(3-Cholamidopropyl)-Dimethylammonio]-1-Propane  sulfonate) 
(CHAPS), 100 mM dithiothretiol (DTT) and 5% (v/v) ampholytes, 5 
tablets/50ml of buffer Mini Complete) was added and incubated at 
RT  for  1hr.  Sample  was  eluted  and  collected  in  microcentrifuge 
tubes by a final centrifugation at 16000g for 1 min. To remove DNA, 
2µl of DNAase-1 were added per 100µl of lysis buffer.
2.2.6.2 Bradford Assay
To  ensure  equal  loading  between  samples  protein  content  was 
quantified by Bradford assay determination. Protein content of BSA 
standards  and  cell  extracts  were  measured  by  the  method  of 
Bradford  (Bradford  1976).  Standards  and  extracts  (20  µl)  were 
diluted in water and mixed with aliquots (180 µl) of Bradford protein 
reagent (Bio-Rad) by vortexing at room temperature. A blank was 
prepared  using  the  same  dilution  of  water:  lysis  buffer  as  the 
samples. Absorbance was measured for each sample in a 96-well 
plate at 590 nm using ELx800TM microplate reader with Gen5 Data 
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Analysis Software. Five serial dilutions of a BSA (500 μg/ml) protein 
standard were made and used to construct a standard curve which 
was subsequently used to determine protein concentration of the 
cell extracts.
2.2.6.3 In-gel rehydration.
In-gel  rehydration  in  a  reswelling  tray  from  Amersham 
Biosciences/GE Healthcare (Little Chalfont, Bucks., UK) was used to 
load samples onto IPG strips. 300µg of sample was brought to a final 
volume of 450µl with rehydration buffer (7 M urea, 2 M thiourea, 
65mM CHAPS, 100 mM DTT and 5% (v/v) ampholytes;  containing 
0.05%  (w/v)  bromophenol  blue  as  tracking  dye).  Samples  were 
gentle  pipetted  into  reswelling  tray  wells,  with  care  taken  to 
distribute samples evenly and without air bubbles. 24cm ph3-10 IPG 
strips were placed gel side down in the reswelling tray and left for 
12 hr.
2.2.6.4 Isoelectric focussing (IEF)
After  re-swelling,  the  IPGstrips  were  loaded  gel  side  up  in  an 
Amersham Ettan IPGphor manifold and covered with 108 ml of cover 
fluid. The following protocol was used;
Time Voltage Mode
21.30 hrs 3500
10m 8000 Grad
4hr 8000 Step
12hr 100v Hold
2.2.6.5 Equilibration of IPG strips
Following isoelectric focusing, IPG strips were equilibrated twice for 
20 minutes
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using 6 M urea, 30% (w/v) glycerol, 2% (w/v) SDS, 100mM Tris-HCl, 
pH 8.8. The first incubation step was performed with the addition of 
100mM  DTT  while  the  second  incubation  step  was  with  0.25  M 
iodoacetamide. The strips were then briefly washed in SDS running 
buffer (0.0125 M Tris, 0.96 M glycine, 0.1% (w/v) SDS) and placed 
on top of a 12.5% (w/v) SDS resolving gels and set using a 1% (w/v) 
agarose sealing gel.
2.2.6.6 Second Dimensional Electrophoresis
The  gel  electrophoretic  separation  in  the  second  dimension  was 
carried  out  by  standard  SDS-PAGE  using  an  Amersham  Ettan 
DALT-Twelve  system  (Doran  et  al., 2006).  Gels  were 
electrophoresed at 1.5 W overnight until the bromophenol blue dye 
front had migrated off the gel.
2.2.6.7 Silver Staining
After electrophoresis, the gels were placed into fixing solution (30% 
ethanol, 10% acetic acid) for a minimum of 30 minutes. The gels 
were then rinsed in 20% ethanol twice for 10 minutes, which was 
followed  by  two  10  minute  washes  in  mili-Q  dH20.  Sensitising 
solution (0.8mM sodium thiosulfate) was poured onto the gels for 
one minute after which the gels were once again washed in milli-Q 
dH20 twice for  two minutes.  The staining solution  (12 mM silver 
nitrate) was then left on the gels for 20 minutes to 2 hours. After the 
staining solution was removed and gels were washed in milli-Q dH20 
for  10  seconds  the  developing  solution  (3%  sodium  potassium 
carbonate,  250ml  formalin,  125  ml  10% sodium thiosulfate)  was 
added to the gel. Once the protein map was visualised the gel was 
placed into stopping solution (40g Tris, 2% actic acid) storing.
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2.2.7  ESI LC/MS
2.2.7.1  Sample Preparation for Mass Spectrometry (MS)
The gel was first washed with deionised water (2 x 10 min) and the 
silver stained spots of  interest were excised from the gels under 
water to prevent contamination and placed into siliconised 1.5 ml 
microcentrifuge tubes.  Silver stain first  had to be destained from 
sample.  Equal  amounts  of  30mM  potassium  ferricynanaide  and 
100mM sodium thiosulphate stocks were added together and 50µl 
added to each gel plug. Plugs were incubated in this solution until 
stain was removed and then washed 3-4 times in deionised water. 
100µl of 200mM Ammonium Bicarbonate was added for 20mins at 
room temperature on shaker. Samples were centrifuged briefly and 
solution  was  removed.  70µl  of  200mM  Ammonium 
Bicarbonate/Acetonitrile  2:3  (v/v)  was  added  to  each  tube  and 
incubated  at  37  degrees  for  15  min  while  shaking.  Again  the 
samples were centrifuged briefly and solution was removed. 70µl of 
50mM Ammonium Bicarbonate was added. After  5 min,  an equal 
volume of acetonitrile was added. After 15 min of incubation all the 
liquid  was  removed  and  the  gel  plugs  were  then  dehydrated  in 
100% acetonitrile. The acetonitrile was removed and the gel plugs 
were  then  dried  down  for  30  min  using  a  Heto  type  vacuum 
centrifuge from Jouan Nordic A/S (Allerod Denmark). Individual gel 
plugs  were  then  rehydrated  in  enough  digestion  buffer  (1mg  of 
trypsin in 20ml of 50mM Ammonium Bicarbonate) to cover the gel 
plugs. Additional digestion buffer was added if all the initial volume 
had  been  absorbed  by  the  gel  pieces.  The  samples  were  then 
incubated at  37ºC over  night.  The peptides  generated by tryptic 
digestion  were  recovered  by  removing  supernatants  from  the 
digested gel plugs. Further recovery was achieved by adding 30% 
acetonitrile/ 0.2% trifluroacetic acid to the gel plugs for 10 min at 
37ºC with gentle agitation. The resulting supernatants were added 
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to  the  initial  peptide  recovery  following  trypsin  digestion.  The 
sample  volume  was  reduced  until  dry  through  vacuum 
centrifugation.  Samples  were  resuspended  in  15  ml  of  ultrapure 
ddH2O and 0.1% formic  acid  for  identification  by ion  trap LC/MS 
(Liquid Chromatography/ Mass Spectrometry) analysis.
2.2.7.2 Ion Trap Mass Spectrometry
The mass spectrometric analysis of peptides was carried out in the 
Proteomics  Suite  of  the  National  University  of  Ireland,  Maynooth 
with  a  Model  6340  Ion  Trap  LC/MS  apparatus  from  Agilent 
Technologies (Santa Clara, CA). Excision,  washing, destaining and 
treatment  with  trypsin  was  performed  by  the  above  optimised 
method.  Separation  of  peptides  was  performed  with  a  nanoflow 
Agilent  1200  series  system,  equipped  with  a  Zorbax  300SB  C18 
5mm, 4mm, 40 nl 71 precolumn and a Zorbax 300SB C18 5 mm, 
43mm x 75mm analytical reversed phase column using HPLC-Chip 
technology (Staples et al., 2009). The mobile phases utilised were A: 
0.1% formic acid, B: 50% acetonitrile and 0.1% formic acid. Samples 
(5ml) were loaded into the enrichment column at a capillary flow 
rate set to 4ml/min with a mix of A and B at a ratio of 19:1 (v/v). 
Tryptic  peptides  were  eluted  with  a  linear  gradient  of  10-90% 
solvent  B  over  15  min  with  a  constant  nano  pump flow  rate  of 
0.60mil/min. At 1 min post time of solvent A was used to remove 
sample carry over. The capillary voltage was set to 2000 V and the 
flow and temperature of the drying gas were 4ml/min and 300°C, 
respectively.  For  protein  identification,  database  searches  were 
carried out with Mascot MS/MS Ion search (Matrix Science, London, 
UK). 
3. Results
lxiii
3.1 Introduction
Elucidating  the  signalling  pathways  propagated  from cell  surface 
receptors  presents  a  major  research  challenge.  However 
understanding of how these signalling events lead to physiological 
effects is essential for discovering how these pathways are altered 
in pathological conditions and developing appropriate therapeutics . 
The innate immune system acts as the first line of defence for the 
body,  acting  to  sense  and  eradicate  invading  microbes.  It  is 
mediated by cells such as monocytes, macophages, neutrophils and 
dendritic  cells,  which  act  to  induce  local  and  systematic 
inflammation, phagocytose microbes and initiate and modulate the 
adaptive immune system . The immune system is a double edged 
sword  in  that  it  is  essential  for  eradicating  infection  but  also 
underlies  inflammatory  diseases  and  thus  must  be  tightly 
regulated . 
Cells  of  the  innate  immune  system  sense  pathogens  through 
pathogen  recognition  receptors  (PPRs).  TLRs  are  the  most 
characterised class of PPRs and can produce proinflammatory and 
anti-viral  responses.  Signalling  through  TLRs,  TNFR1  and  IL-IR 
converge on the activation of the kinase TAK1 which phosphorylates 
and  activates  IKK  proteins.  IKK  proteins  can  phosphorylate  IκB, 
leading to IκB degradation and the release of the proinflammatory 
transcription  factor  NFκB  to  induce  changes  in  gene  expression. 
TAK1  activation  simultaneously  leads  to  the  activation  of  MAPK 
proteins by activating both MAPKKK and MAPKK proteins. The MAPKs 
are involved in the induction of gene expression, as well as playing 
roles in the regulation of mRNA stability. Detection of viral particles 
by  TLRs  mediates  an  anti-viral  interferon  response  through  the 
activation of IRF transcription factors, NFκB and MAPKs . Since the 
discovery of TLRs in the 1990s, deciphering of TLR signalling has 
been  the  focus  of  many  research  groups.  Indeed  it  has  been 
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acknowledged that signalling by TLRs does not induce simple linear 
pathways but that they integrate into complex signalling networks 
that ultimately control the physiological response. 
Some of the earliest work on TLRs led to the discovery of the protein 
ECSIT. It was discovered in 1999 by Kopp et al., which identified it 
as a TRAF6 interaction protein through a yeast two hybrid screen. 
Murine ECSIT (mECSIT) was found to enhance NFκB responses and 
lead  to  MEKK1  modulation.  Since  then,  mECSIT  has  been 
characterised  as  a  mitochondrial  localised  protein,  involved  in 
mitochondrial  complex  assembly  and  mitochondrial  signalling. 
Knockout of mECSIT results in embryonic lethality, which led to the 
discovery that mECSIT was involved in BMP signalling. The Moynagh 
Lab  is  concerned  with  the  human  orthologue  of  ECSIT,  hECSIT, 
which was cloned by members of this lab. To date no functional data 
on hECSIT has been published. However extensive research in the 
Moynagh Lab has characterised hECSIT as a negative regulator of 
NFκB activation.  My project  focussed  on  the  ability  of  hECSIT  to 
regulate the MAPK pathways and to explore the mechanistic basis to 
any effects of ECSIT on the MAPK pathways.  
3.2 Results
3.2.1 hECSIT and mECSIT display differential effects on NFκB 
activation.
Kopp et al., (1999) characterised mECSIT as a positive intermediate 
of  NFκB  activation;  it  can  induce  NFκB  activation  and  enhances 
NFκB activation in response to IL-1β and LPS signalling. The present 
study  compared  the  efficacies  of  the  hECSIT  and  mECSIT  in 
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activating  NFκB  as  measured  by  induction  of  a  NFκB-dependent 
reporter gene. HEK 293 TLR4 cells were transiently transfected with 
hECSIT  or  mECSIT  expression  constructs  and  assayed  for  their 
ability to induce the expression of a co-transfected NFĸB-regulated 
firefly luciferase gene (Figure 3.1). As shown by Kopp et al., (1999), 
mECSIT  induces  NFĸB  activation.  In  contrast  hECSIT  fails  to 
up-regulate  NFĸB activation.  Following  IL-1β  and LPS stimulation, 
mECSIT further enhances the activation of NF-ĸB. hECSIT however 
does not  up-regulate  IL-1β  and LPS induced NFĸB activation  and 
displays  slight  inhibitory  effects  on  the  ability  of  IL-1  to  activate 
NFkB.
3.2.2 Numerous forms of hECSIT can be detected by Mass 
Spectromerty.
 
Given that the human form of ECSIT fails to mimic the functional 
capacity of its murine equivalent, we were keen to study the human 
form in more detail with a view to providing some understanding of 
its  function.  With  this  in  mind  we  applied  a  proteomics-based 
approach  to  identify  ECSIT-interacting  proteins  that  may  provide 
clues to its function. HEK 293 T cells were transiently transfected 
with  or  without  a  MYC-tagged  hECSIT  expression  construct.  The 
following day cell lysates were generated and immunoprecipitated 
using an anti-MYC antibody. Western blotting was used to confirm 
the  presence  of  MYC-tagged  ECSIT  in  the  immunoprecipitated 
samples (Figure 3.2).  Immunoprecipitates were then subjected to 
two-dimensional  gel  electrophoresis  and  stained  with  silver  stain 
solution  (Figure  3.3).  8  proteins  spots,  unique  to  samples 
overexpressing hECSIT, were cut from the gels and  identified by 
mass spectrometry (Table 3.1). Five of the spots were identified as 
hECSIT  based  on  mass  spectrometry  and  MASCOT  anaylsis, 
indicating  the  presence  of  various  modified  forms  of  hECSIT. 
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Furthemore the probing of the 2-D gels with an anti-hECSIT antibody 
confirmed  the  presence  of  hECSIT  at  those  spots  previously 
identified as hECSIT by Ion-trap Mass Spectrometry (Figure 3.4). 3 
other  proteins  were  identified  by  mass  spectrometry,  they  were 
dystroglycan, leukotriene C4 synthase and Zinc finger protein 419. 
Two of these proteins, dystrogylcan and leuokotriene C4 synthase 
have been characterised previously. In skeletal muscle dystroglycan 
forms part of large complex that functions to link the extracellular 
matrix  to the cytoskeleton.  While  it  is  expressed in tissues other 
than muscle, its function in them is not fully known . Leukotriene C4 
synthase is an enzyme that converts leukotriene A4 and glutathione 
into leukotriene C4, a step in the production of leukotrienes from 
arachidonic  acid  .  Leukotrienes  are  critical  to  the  inflammatory 
response,  acting  on  cell  surface  receptors  to  promote 
bronchoconstriction,  increase  vascular  permability  and  cell 
adherence amongst other  roles  .  In  contrast to dystroglycan and 
leukotrience C4 synthase, there was minimal information available 
on the function of ZNF419 . ZNF419 has been characterised in terms 
of potential domains, and contains a zinc finger domain. Zinc finger 
domains are present in several  key TLR proteins and therefore it 
was decided to further probe the interaction of hECSIT and ZNF419 
and  the  role  of  ZNF419  in  TLR  signalling  ; Jaaflela  et  al., 1996; 
Minoda et al., 2006; Wallis et al., 2003).
3.2.3 hECSIT fails to co-immunoprecipitate with ZNF419.
ZNF419 was identified by Ion-trap Mass Spectrometry as a hECSIT 
interacting  protein.  It  was  selected  for  further  analysis  as  zinc 
fingers domains have been shown to be important in TLR signalling 
proteins.  We  aimed  to  confirm  this  interaction  by  assessing  if 
hECSIT-MYC  co-immunoprecipitates  with  ZNF419.  We  initially 
planned to study the interaction of hECSIT with endogenous ZNF419 
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but the commercially available anti-ZNF419 failed to detect ZNF419 
(at its molecular weight of 59kDA) even when cells were transfected 
with  an  expression  construct  encoding  ZNF419  (Figure  3.5). 
Therefore hECSIT was next examined for its ability to interact with 
overexpressed ZNF419 that was FLAG tagged.  HEK 293 cells were 
transiently  co-transfected  with  ZNF419-FLAG  constructs,  with  or 
without MYC-tagged hECSIT construct. The following day cell lysates 
were generated and immunoprecipitated using anti-MYC antibody. 
Immunoprecipitates were then analysed for protein interaction by 
Western  immunoblotting  using  FLAG  antibody.   Whilst 
immunoprecipitation of hECSIT was confirmed by anti-MYC blotting, 
ZNF419  was  not  detectable  in  the  hECSIT-immunoprecipitated 
samples  (Figure  3.6).  Immunoblotting  with  an  anti-HA  antibody 
confirmed overexpression of ZNF419. 
3.2.4 ZNF419 does not affect NFκB activation. 
Although we failed to confirm interaction of ZNF419 with hECSIT, we 
were keen to assess if the former could regulate pathways such as 
NFkB that have been associated with ECSIT. Furthemore zinc finger 
containing proteins are known to regulate several  aspects of  TLR 
signalling (Jaaflela  et al., 1996; Minoda  et al., 2006) and thus we 
probed if ZNF419 could regulate NFκB signalling. HEK 293 TLR4 cells 
were  transiently  transfected  with  or  without  ZNF419-FLAG 
expression constructs and assayed for their ability to regulate the 
expression  of  a  co-transfected  NFĸB-dependent  reporter  gene. 
ZNF419 failed to activate NFκB in this  assay system and had no 
affect on the ability of LPS, IL-1β or TNFα to activate NFκB (Figure 
3.7). 
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3.2.5  Knockdown  of  endogenous  hECSIT  by  lentiviral 
encoding  shRNA  constructs  decreases  the 
phosphorylation  of  SMAD1-5-8  while  increasing  the 
phosphorylation of p42/44 at basal levels. 
Given that hECSIT fails to mimic mECSIT in activating NFκB and our 
proteomics-based  screen  did  not  reveal  novel  ECSIT-interacting 
proteins we next probed the potential role of hECSIT as a regulator 
of  other pathways that are associated with mECSIT.   Xiao  et al., 
(2003) reported that knockout of ECSIT in murine models resulted in 
embryonic lethality and a phenotype that was very similar to loss of 
BMP1R. Further investigation revealed mECSIT was critical to BMP 
signalling  and  was  essential  for  mesoderm  formation  during 
embryonic development. We thus assessed the function of hECSIT in 
BMP4  signalling.  BMP4  signals  through  the  BMPR1  receptor  and 
propagates signalling through SMAD proteins, SMAD 1, SMAD 5, and 
SMAD8 (SMAD 1-5-8) . In order to examine the role of hECSIT in the 
BMPR1  pathway,   the  endogenous  expression  of  hECSIT  was 
suppressed  using  lentiviral-deliver  hECSIT  specific  shRNAs  and 
examined for  effects on activation of SMAD 1-5-8 following BMP4 
stimulation.  A549 cells  are  human adencarcinomic  alveolar  basal 
epithelial  cells,  they  show increased  activation  of  SMAD 1-5-8  in 
response to BMP4 stimulation and thus were chosen as the cell line 
for  the purpose of  this  study.  Lentivirus was initially  produced in 
HEK  293  T  cells  by  co-transfecting  packaging  and  envelope 
expression constructs with shRNA vectors encoding hECSIT-specific 
shRNA  or  control  shRNA  (that  doesn’t  target  any  human  gene). 
Media containing lentivirus was collected 48h post-transfection and 
then used to infect A549 cells in the presence of polybrene (8μg/ml) 
to  improve  infection  efficiency.  Virus  was  removed  24h 
post-infection,  cells  were  then  cultured  in  the  presence  of  a 
selective reagent puromycin (5μg/ml) to ensure stable integration of 
shRNA  was  obtained.  To  confirm  selective  knockdown  of 
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endogenous  hECSIT  shRNA,  cell  lysates  were  generated  and 
subjected  to  Western  immunoblotting  using  ECSIT-specific 
antibodies. hECSIT shRNA clone A7 showed very strong knockdown 
of hECSIT protein expression while control shRNA had no effect on 
hECSIT  expression  (Figure  3.9).  The  A549  cell  lines  with  stably 
integrated shRNA constructs were stimulated with BMP4 for various 
time periods from 0’,  15’,  45’ up to 180’ min. Cell  extracts were 
then  generated  and  probed  for  phosphorylation  of  SMAD  1-5-8 
(Figure 3.9). BMP4 induced phosphorylation of SMAD 1-5-8 at 15min 
and  peaked at   45’  min  in  cells  that  had  been  transduced  with 
lentivirus  containing  control  shRNA.  Knockdown  of  hECSIT 
expression  with  hECSIT-specific  shRNA  greatly  reduced 
Smad-induced phosphorylation by BMP-4. These data suggest that 
hECSIT  mimics  the  role  of  its  murine  counterpart  in  the  BMPR1 
pathway. In order to assess if this role is specific for regulation of 
Smad  phosphorylation  we  also  probed  the  role  of  hECSIT  in 
SMAD-independent pathways that are also triggered by BMPRI. BMP 
stimulation can also activate SMAD-independent pathways, of which 
p42/44 MAPK is a known target (Li  et al., 2012; Zhou et al., 2007). 
BMP4  promoted  low  level  phosphorylation  of  p42/44  in  cells 
transduced  with  control  shRNA.  Increased  phosphorylation  was 
apparent at 15’ min post BMP4 stimulation and declined to basal 
levels by 180’ min. However suppression of hECSIT caused strong 
increases in the basal and BMP4-induced levels of phosphorylated 
p42/44  (Figure  3.8).   All  samples  displayed  equivalent  levels  of 
β-actin demonstrating that the changes in SMAD 1-5-8 and p42/44 
phosphorylation  were  not  due to  non-specific  changes in  general 
protein expression. 
 
3.2.6 hECSIT fails to interact with SMAD4.
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Xiao et al., (2003) showed that mECSIT could interact with SMAD4 to 
regulate its function. Given that the above findings indicated that 
hECSIT may be able to regulate Smad phosphorylation, I assessed 
the interaction of hECSIT and SMAD4. HEK 293 cells were transiently 
co-transfected with HA-tagged SMAD4 with or without MYC-tagged 
hECSIT construct. The following day cell lysates were generated and 
immunoprecipitated  using  anti-MYC  antibody.  Immunoprecipitates 
were  then  analysed  for  the  presence  of  SMAD4  by  Western 
immunoblotting  using  anti-HA  antibody.  Unlike  its  murine  form, 
hECSIT  shows  no  interaction  with  SMAD4  (Figure  3.9).  The 
expression  of  MYC-hECSIT  and  HA-SMAD4  were  confirmed  by 
probing WCL with anti-MYC and anti-HA antibodies respectively. The 
immunoprecipitation  of  MYC-hECSIT  was  confirmed  by  probing 
co-immunoprecipitation samples with an anti-MYC antibody. 
3.2.7 Knockdown of endogenous hECSIT by lentiviral 
encoding shRNA constructs enhances phosphorylation 
of p42/44.
Since suppression of  hECSIT resulted in strong induction   p42/44 
phosphorylation in response to BMP4, we next examined if hECSIT 
could regulate p42/44 phosphoryaltion  in TLR signalling pathways. 
A549 stable cell lines were again transduced with lentiviral particles 
containing  hECSIT-specific  shRNA  and  stable  cell  lines  were 
generated  showing  suppressed  expression  of  hECSIT.  Cells  were 
treated with LPS for various time periods, cell  extracts generated 
and subjected to Western immunoblotting. LPS promoted increased 
phosphorylation of p42/44 in cells transduced with control shRNA. 
Suppression of hECSIT resulted in greatly enhanced phosphorylation 
of basal p42/44 phosphorylation that was not further augmented by 
LPS (Figure 3.10). This is comparable with results obtained following 
lxxi
BMP4 signalling (Figure 3.8). From these results it appears hECSIT 
plays a role in controlling basal phosphorylation of p42/44. 
3.2.8 hECSIT and mECSIT display differential effects on the 
activation of ELK-1.
Given that hECSIT can regulate basal phosphorylation of p42/44 we 
next  probed  the  downstream  functional  consequences  of  such 
regulation. ELK-1 is a transcription factor involved in the induction of 
genes such as c-fos which forms vital part of AP-1 complex. It can be 
activated and phosphorylated by p42/44 and also by p38 and JNK . 
HEK  293  TLR4  cells  were  co-transfected  with  pFA-ELK-1 
trans-activator plasmid in conjunction with pFR-luciferase construct 
with or without hECSIT or mECSIT plasmid constructs. The following 
day cells were treated with IL-1β or LPS for 6hr. Cell lysates were 
then generated and assayed for ELK-1 regulated luciferase activity. 
Similar to regulation of NF-ĸB, hECSIT and mECSIT display opposing 
effects  on  activation  of  ELK-1  (Figure  3.11).  Neither  hECSIT  or 
mECSIT induce ELK-1 activation. However mECSIT enhances ELK-1 
activation  following  IL-1β  and  LPS  treatment.  In  contrast  hECSIT 
displays  marginal  inhibitory  effects  on  IL-1β  and  LPS-induced 
activation of ELK-1. The inhibitory affects of hECSIT on ELK-1 are 
consistent with the inhibitory effects of hECSIT on upstream p42/44 .
3.2.9 hECSIT and mECSIT display differential effects on AP-1 
activation.
A key  consequence  of  ELK-1  activation  is  the  induction  of  c-fos 
expression, an Ap-1 subunit. AP-1 is key transcription factor induced 
by  MAPK  to  mediate  innate  immune  responses.  It  is  a  dimeric 
protein composed primarily of  c-fos and c-jun proteins .  HEK 293 
TLR4  cells  were  transiently  transfected  with  hECSIT  or  mECSIT 
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expression constructs with or without a MyD88 expression construct 
and  assayed  for  their  ability  to  induce  the  expression  of  a 
co-transfected  AP-1-  dependent  reporter  gene.  The following  day 
cell  lysates  were  generated  and  assayed  for  AP-1  regulated 
luciferase activity.  hECSIT and mECSIT displayed opposing effects 
on  activation  of  AP-1  (Figure  3.12).  mECSIT  enhances  MyD88 
induced AP-1  activation, while in contrast hECSIT displays inhibitory 
effects on MyD88 induced activation of AP-1.
3.2.10 Overexpression of hECSIT decreases MEKK1 induced 
phosphorylation of p42/44.
The luciferase assays detailed above indicate that overexpression of 
hECSIT  has  an  inhibitory  affect  on  the  activation  of  p42/44. 
Furthermore Kopp et al., (1999) reported that mECSIT was involved 
in processing of MEKK1. MEKK1 is a MAP kinase kinase kinase that is 
an upstream regulator of all 3 classes of MAPKs including p42/44. 
Thus hECSIT was investigation for its potential to regulate MEKK1 
activation of the various MAPKs. HEK 293 cells were co-transfected 
with  MEKK1-encoding  construct  and  increasing  amounts  of 
hECSIT-encoding  constructs.  The  following  day  cell  lysates  were 
generated  and  subjected  to  western  immunoblotting  using 
antibodies  against  the phosphorylated and total  forms of  p42/44, 
p38 and JNK.   The overexpression of  MEKK1 promoted  increased 
phosphorylation  of  all  3  MAPKs.  Intriguingly  the  co-expression  of 
hECSIT stongly inhibited MEKK1-induced phosphoryation of p42/44 
whilst leaving the levels of phosphorylated p38 and JNK relatively 
unaffected  (Figure  3.13).  This  data  indicates  a  strong  degree  of 
specificity for hECSIT in regulating the p42/44 pathway. 
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3.2.11 Suppression of endogenous hECSIT by lentiviral 
encoding shRNA constructs increases the 
phosphorylation of p42/44.
Given the strong effect of shRNA-mediated knockdown of hECSIT on 
phosphorylation of p42/44 in A549 cells we were eager to show that 
this effect was not an artefact of the A549 cell  line and thus we 
performed  similar  shRNA  knockdown  studies  in  U373  cells.  The 
latter are brain astrocytic cells that respond to LPS, IL-1β and TNFα. 
U373 cells stably expressing hECSIT specific shRNA constructs were 
produced as  described in  section  3.2.5.  The U373 cell  lines  with 
stably  integrated  shRNA constructs  were  stimulated  with  LPS  for 
various time periods. Cell extracts were then generated and probed 
for  the  phosphorylation  of  p42/44,  p38  and  JNK.  Knockdown  of 
hECSIT  with  shRNA increased  the  basal  levels  of  phosphorylated 
p42/44  and this  was further  augmented by  LPS (Figure  3.14).  In 
control samples, the levels of p42/44 phosphorylation decrease to 
near basal levels by 180’ minutes, however when hECSIT levels are 
suppressed the levels of p42/44 phosphorylation remain elevated. 
The  phosphorylation  of  p38  and  pJNK  are  comparable  between 
control shRNA and hECSIT shRNA. All samples displayed equivalent 
levels of total p42/44, p38, JNK and β-actin demonstrating that the 
changes  in  p42/44  phosphorylation  were  not  due  to  non-specific 
changes in general protein expression. 
The  effect  of  hECSIT  suppression  on  p42/44  phosphorylation  in 
response to IL-1β (Figure 3.15)  and TNFα (Figure 3.16)  signalling 
was also determined. As with LPS stimulation, the levels of p42/44 
phosphorylation are greatly enhanced when hECSIT is suppressed, 
while there is no significant effect on the phosphorylation of p38 and 
JNK.  β-actin  levels  are  consistant  throughout  the  samples 
demonstrating that the changes in p42/44 phosphorylation were not 
due to changes in protein levels. 
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3.2.12 Suppression of endogenous hECSIT by siRNA 
increases the phosphorylation of p42/44.
Given the strong effect of shRNA-mediated knockdown of hECSIT on 
phosphorylation of p42/44 in A549 and U373 cells we were keen to 
shown that this effect was not an artefact of the shRNA knockdown 
approach,  we  thus  complemented  this  approach  by  using 
siRNA-mediated knockdown of hECSIT in U373 cells. U373 cells were 
transfected with Lamin a/c control siRNA or hECSIT-specific siRNA. 
48hrs post tranfection cells were treated with LPS at various time 
points from 0’, 5’, 10’ 30’, 60’ up to 180’ mins. Cells lysates were 
extracted  and  subjected  to  western  blotting  and  probed  with 
antibodies  against  the  phosphorylated  and total  forms of  p42/44 
and p38. In control siRNA-transfected  cells, basal levels of p42/44 
phosphorylation are low and peak at 60 min post LPS stimulation. 
Tranfection  of  cells  with  hECSIT-specific  siRNA  caused  strong 
suppression of hECSIT expression and this lead to greatly increased 
basal levels of p42/44 that were further enhanced by LPS (Figure 
3.17).  The phosphorylation of p38 is comparable between control 
siRNA and hECSIT  siRNA again  indicating that  hECSIT  specifically 
targets the p42/44 pathway. Total levels of p42/44 and p38 remain 
constant across the samples, while all samples displayed equivalent 
levels  of  β-actin  demonstrating  that  the  changes  in  p42/44 
phosphorylation  were  not  due to  non-specific  changes in  general 
protein expression. 
3.2.13 hECSIT does not affect the processing of p105 to p50.
While  p38,  JNK  and  p42/44  are  members  of  the  same family  of 
proteins, they have distinct roles and are activated differentially in 
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response to different ligands. They differ in the upstream kinases 
that  can  activate  them,  with  each  having  distinct  MAPKKK  and 
MAPKK that  can solely  or  preferentially  activate  them.   Tpl2  has 
been shown to be critical to the activation of p42/44 but not other 
MAPKs (Rousseau  et al., 2005).  As hECSIT specifically targets the 
regulation of phosphorylation of p42/44 but not that of p38 and JNK, 
I postulated that hECSIT could be acting at the level of Tpl2. Tpl2 
stability  depends  on  its  interaction  with  p105,  while  partial 
degradation  of  p105  into  the  p50  form  is  necessary  for  Tpl2 
signalling. I investigated if hECSIT regulated the levels of p105 or its 
processing in response to LPS signalling (Beinke et al., 2003). Stable 
hECSIT knockdown U373 cell lines were generated as before using 
hECSIT  specific  shRNA.  Cells  were  treated  with  LPS  at  various 
timepoints. Following stimulation, cell lystates were generated and 
subjected to western blotting. They were probed with anti-p105/p50 
antibody.  The levels  and degradation  of  p105 over the indicated 
timecourse  were  comparable  between control  and hECSIT  shRNA 
samples, implying hECSIT does not affect the processing of p105 
(Figure  3.18).  Suppression  of  hECSIT  results  in  increased  p42/44 
phosphorylation as shown previously. 
3.2.14 hECSIT does not interact with TPL2
Tpl2 has been shown to form a signalling complex with p105 and 
ABIN2  which  regulates  the  stability  and  activation  of  Tpl2.  We 
hypothesised  that  hECSIT  may  exert  its  affect  on  p42/44 
phosphorylation by interacting with Tpl2. I investigated this possible 
interaction.  HEK  293  cells  were  transiently  co-transfected  with 
HA-tagged Tpl2 with or without MYC-tagged hECSIT construct. The 
following day cell lysates were generated and immunoprecipitated 
using anti-MYC antibody.  Immunoprecipitates  were  then analysed 
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for  protein  interaction  by  Western  immunoblotting  using  anti-HA 
antibody. The expression of the plasmids was confirmed by probing 
whole  cell  lysates  with  anti-HA  antibody  and  anti-MYC  antibody, 
while the immunoprecitation of MYC-tagged hECSIT was confirmed 
by  probing  immunoprecipitates  with  anti-MYC  antibody.  hECSIT 
showed no interaction with Tpl2 (Figure 3.19). 
3.3 Figures
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Figure 3.1 hECSIT and mECSIT display differential effects on 
IL-1β and LPS-induced NF-ĸB activation. 
HEK293 TLR4 cells were co-transfected with  NFĸB firefly luciferase 
reporter construct (80ng), TK Renilla (20ng) and hECSIT or mECSIT 
(100ng). Empty Vector (EV) pcDNA3.1 was used to normalise total 
amount of  DNA.  The following day cells  were treated with either 
IL-1β (10ng/ml) or  LPS (100ng/ml)  for  6h.  Cell  lysates  were then 
generated  and  assayed  for  firefly  and  Renilla luciferase  activity. 
Results represent mean +/- SD of triplicate determinations and is a 
representative of three independent experiments.
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Figure  3.2  Confirmation  of  immunoprecitation  of  hECSIT- 
MYC. 
HEK 293 T cells were transfected with 1ug hECSIT-MYC or control EV 
PcDNA (CTRL). The following day cell  lysates were harvested and 
subjected  to  immunoprecipiatation  with  anti-MYC  antibody.  To 
confirm  the  specific  immunoprecipiation  of  hECSIT-MYC,  samples 
were subjected to SDS-PAGE separation and western blotting with 
anti-MYC antibody. 
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Figure  3.3   2-D  electrophoresis  of  proteins 
co-immunoprecipitating with hECSIT 
lxxx
HEK 293 T cells were transfected with 1ug hECSIT-MYC (A) or control 
EV PcDNA (B). The following day cell  lysates were harvested and 
subjected to immunoprecipiatation with anti-MYC antibody. Protein 
concentration was measured by Bradford assay and equal amounts 
of  coimmunoprecipitates  (100µg)  were  separated  in  the  first 
dimension by isolelectric focusing on pH 3-10 18mm IEF strips and 
in the second dimension by SDS-PAGE. Proteins were visualised by 
silver staining.  
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Spot # Name Gene ID Gene Decription
1 ECSIT 51295 ECSIT homolog (Drosophila)
2 ECSIT 51295 ECSIT homolog (Drosophila)
3 ECSIT 51295 ECSIT homolog (Drosophila)
4 ECSIT 51295 ECSIT homolog (Drosophila)
5 ECSIT 51295 ECSIT homolog (Drosophila)
6 DAG1 1605 dystroglycan  1 
(dystrophin-associated 
glycoprotein 1)
7 LTC4 4056 leukotriene C4 synthase
8 ZNF419 79744 Zinc Finger Protein 419
Table  3.1  Ion-trap  Mass-spectrometry  identified  proteins 
that  interact  with  hECSIT.  Criteria  thresholds  were 
lowered  to  minimum  criteria  to  achieve  maximum 
peptide  hits.  Any  identified  proteins  were  then 
validated by molecular means to determine the results.
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Figure 3.4 hECSIT undergoes various forms of modification
HEK  293  T  cells  were  transfected  with  1ug  hECSIT-MYC.  The 
following  day  cell  lysates  were  harvested  and  subjected  to 
immunoprecipiatation  with  anti-MYC  antibody.  Samples  were 
separated in the first dimension by isolelectric focusing on pH 3-10 
18mm IEF strips  and in  the second dimension by SDS-PAGE and 
subsequently  subjected  to  western  blotting  with  anti-hECSIT 
antibody.  
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Figure 3.5 Anti-ZNF419 fails to detect overexpressed 
ZNF419
HEK293 cells were transfected with increasing amounts of plasmid 
encoding ZNF419 (0.5, 0.8. 1, 1.5 and 2 µg). The empty vector (EV) 
pcDNA3.1  was  used  as  a  negative  control.  Cell  lysates  were 
generated the following day and subjected to SDS-PAGE separation. 
Western blotting was preformed probing with anti-ZNF419 antibody. 
β-actin was used as a loading control.
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Figure 3.6 ZNF419 fails to co-immunoprecipitate with hECSIT
Hek 293 T cells were transfected with 1 µg hECSIT-MYC and/or 1µg 
ZNF419-FLAG as indicated. DNA levels were normalised with empty 
vector pcDNA3.1. Lysates were harvested 24 h post-tranfection and 
immunoprecipitated  with  an  immobilised  anti-MYC  antibody. 
Immunoprecipitates  were  subjected  to  polyacrylamide  gel 
electrophoresis and subsequently to Western immunoblotting using 
an anti-FLAG antibody. They were probed with anti-MYC antibody to 
confirm the co-immunoprecipitation. Whole cell lysates (WCL) were 
also  analysed  by  Western  blotting  with  anti-MYC  and  anti-FLAG 
antibody  to  confirm  expression  of  plasmids.  Immunoprecipitation 
blot shown above is representative of two independent experiments.
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Figure 3.7 ZNF419 does not affect LPS, IL-1β or TNFα 
induced activation of NFκB.
HEK293 TLR4 cells were transfected with NFκB-luciferase (80ng), TK 
renilla (20ng) with or without ZNF419-FLAG (100ng). EV PcDNA3.1 
was used to equalise DNA concentration, while TK renillla was used 
to normalise for transfection efficiency. The following day cells were 
treated with LPS (100ng/ml), IL-1β (10ng/ml) or TNFα (50ng/ml) and 
harvested after 6h. Cells lysates were assayed for firefly luciferase 
and TK Renilla luciferase. Results represent mean +/- SD of triplicate 
determinations  and  is  a  representative  of  two  independent 
experiments.
lxxxvi
          
 
         
Figure 3.8 Knockdown of  endogenous hECSIT in  the A549 
cell  line  decreases  the  phosphorylation  of  receptor 
regulated  SMAD  proteins  (SMAD1-5-8)  and  enhances 
the  phosphorylation  of  p42/44  following  BMP-4 
stimulation.
A549 cells were transduced with hECSIT-specific lentiviral shRNA or 
Control  shRNA.  Cells  were  cultured  in  the  presence  of  selective 
reagent puromycin (5μg/ml). Knockdown of endogenous hECSIT was 
confirmed by immunoblotting. Once achieved, the cells were then 
treated with BMP-4 (50ng/ml) for various time points (15, 45 and 
180min).  Cell  lysates  were  then  generated  and  subjected  to 
SDS-PAGE  and  subsequently  to  Western  immunoblotting with 
antibodies  against  phosphorylated  SMAD  1-5-8  (p-SMAD), 
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phosphorylated P42/44 (p-P42/44) and ECSIT.  β-actin was used as a 
loading control. These results are representative of two independent 
experiments.
             
Figure 3.9  Smad4 fails to co-immunoprecipitate with hECSIT
HEK 293 T cells were transfected with 1 µg hECSIT-MYC and/or 1µg 
Smad4-HA as  indicated.  DNA levels  were  normalised  with  empty 
vector pcDNA3.1. Lysates were harvested 24 h post-tranfection and 
immunoprecipitated  with  an  immobilised  anti-MYC  antibody. 
Immunoprecipitates  were  subjected  to  polyacrylamide  gel 
electrophoresis and subsequently to Western immunoblotting using 
an anti-HA antibody. They were subsequently probed with anti-MYC 
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antibody to confirm the co-immunoprecipitation. Cell  lysates were 
also analysed by Western immunoblotting to confirm expression of 
the  constructs.  Immunoprecipitation  blot  shown  above  is 
representative of two independent experiments.
            
Figure 3.10 Knockdown of endogenous hECSIT in the A549 
cell line results in increased phosphorylation of p42/44 
following LPS stimulation.
A549 cells were transduced with hECSIT-specific lentiviral shRNA or 
Control  shRNA.  Cells  were  cultured  in  the  presence  of  selective 
reagent puromycin (5μg/ml). Knockdown of endogenous hECSIT was 
confirmed by immunoblotting. Once achieved, the cells were then 
treated  with  LPS  (100ng/ml)  for  various  time  points  (20,  60, 
180min).  Cell  lysates  were  then  generated  and  subjected  to 
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SDS-PAGE  and  subsequently  to  Western  immunoblotting with 
antibodies  against  phosphorylated  P42/44  (p-P42/44).  hECSIT 
knockdown  was  confirmed  by  probing  with  anti-hECSIT  antibody. 
β-actin  was  used  as  a  loading  control.These  results  are 
representative of two independent experiments.
   
Figure  3.11  Differential  effects  of  hECSIT  and  mECSIT  on 
IL-1β and LPS induced ELK-1 activation.
HEK293  TLR4  cells  were  transfected  with  ELK-1-gal4  (30ng),  the 
gal4  responsive  promoter  pFR-ELK-1  luciferase  (80ng),  tk  renilla 
(20ng)  and either  hECSIT or  mECSIT  (100ng).  EV PcDNA3.1  was 
xc
used to equalise DNA concentration,  while tk renillla was used to 
normalise  transfection  efficiency.  The  following  day  cells  were 
treated  with  or  without  IL-1β  (10ng/ml)  or  LPS  (100ng/ml)  and 
harvested after 6h. Cells lysates were assayed for firefly luciferase 
and TK Renilla luciferase. Results represent mean +/- SD of triplicate 
determinations  and  is  a  representative  of  two  independent 
experiments.
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Figure  3.12  Differential  effects  of  hECSIT  and  mECSIT  on 
MYd88 induced activation of AP-1.
Hek293  T  cells  were  cotransfected  with  ap-1 luciferase  (80g),  tk 
renilla (20ng), hECSIT or mECSIT (100ng), and Myd88 (50ng). PcDNA 
was used to normalise DNA concentration, while TK renilla was used 
to  normalise  tranfection  efficiency.  Cells  were  harvested  the 
following day and lysates were assayed for firefly luciferase and TK 
renilla. Results represent mean +/- SD of triplicate determinations 
and is a representative of two independent experiments.
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Figure  3.13  hECSIT  inhibits  the  MEKK1  induced 
phosphorylation of p42/44 but not p38 and JNK.
HEK293 cells  were  transfected with  various  amounts  of  plasmids 
encoding hECSIT (0.5, 1, and 1.5 µg), and MEKK1 (.5µg). The empty 
vector (EV) pcDNA3.1 was used as a negative control. Cell lysates 
were  generated  the  following  day  and  subjected  to  SDS-PAGE. 
Levels  of  phosphorylated p38 (p-p38),  p42/44 (p-p42/44) and JNK 
(p-JNK) and total p38, p42/44 and JNK were assessed by Western 
immunoblotting. β-actin was used to measure total protein levels in 
samples.
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Figure 3.14 Knockdown of endogenous hECSIT in the U373 
cell  line  enhances  the  phosphorylation  of  p42/44 
following LPS stimulation.
U373  cells  were  polyclonally  transduced  with  hECSIT-specific 
lentiviral  shRNA  or  Control  shRNA.  Cells  were  cultured  in  the 
presence of  selective  reagent  puromycin  (5μg/ml).  Knockdown of 
endogenous  hECSIT  was  checked  by  immunoblotting.  Once 
achieved,  the  cells  were  then  treated  with  LPS  (100ng/ml)  for 
various time points (5,10, 30, 60, 180mins). Cell lysates were then 
generated  and  subjected  to  SDS-PAGE.  Levels  of  phosphorylated 
p38  (p-p38),  p42/44  (p-p42/44)  and  JNK  (p-JNK)  and  total  p38, 
p42/44 and JNK were assessed by Western β-actin was used as a 
loading control.These results are representative of two independent 
experiments.
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Figure 3.15 Knockdown of endogenous hECSIT in the U373 
cell line enhances phosphorylation of p42/44 following 
IL-1β stimulation.
U373  cells  were  polyclonally  transduced  with  hECSIT-specific 
lentiviral  shRNA  or  Control  shRNA.  Cells  were  cultured  in  the 
presence of  selective  reagent  puromycin  (5μg/ml).  Knockdown of 
endogenous  hECSIT  was  checked  by  immunoblotting.  Once 
achieved,  the  cells  were  then  treated  with  IL-1β  (10ng/ml)  for 
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various time points (5,10, 30, 60, 180mins). Cell lysates were then 
generated  and  subjected  to  SDS-PAGE.  Levels  of  phosphorylated 
p38  (p-p38),  p42/44  (p-p42/44)  and  JNK  (p-JNK)  and  total  p38, 
p42/44 and JNK were assessed by Western immunoblotting β-actin 
was used as a loading control.  These results are representative of 
two independent experiments.
        
                               
Figure 3.16 Knockdown of endogenous hECSIT in the U373 
cell line enhances phosphorylation of p42/44 following 
TNF-α stimulation.
U373  cells  were  polyclonally  transduced  with  hECSIT-specific 
lentiviral  shRNA   or  Control  shRNA.  Cells  were  cultured  in  the 
presence of  selective  reagent  puromycin  (5μg/ml).  Knockdown of 
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endogenous  hECSIT  was  checked  by  immunoblotting.  Once 
achieved,  the  cells  were  then  treated  with  TNF-α  (50ng/ml)  for 
various time points (5,10, 30, 60, 180mins). Cell lysates were then 
generated  and  subjected  to  SDS-PAGE.  Levels  of  phospho-p38, 
phospho-p42/44, phospho-JNK and total p42/44, were assessed by 
Western  immunoblotting. β-actin  was  used  as  a  loading  control. 
These results are representative of two independent experiments.
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Figure  3.17  Knockdown  of  hECSIT  with  siRNA  augments 
1L-1β induced phosphorylation of p42/44.
U373 cells were transfected with hECSIT siRNA (10nm). Cells were 
harvested 48hrs later in RIPA buffer. 3 hrs before harvesting cells 
were treated with IL-1β at indicated times (5, 10, 30, 60 and 180 
mins).  Whole  cell  extracts  were  generated  and  subjected  to 
SDS-PAGE.  Levels  of  phosphorylated  p38  (p-p38)  and  p42/44 
(p-p42/44)  and  total  p38  and  p42/44  were assessed  by  Western 
immunoblotting..  β-actin  was  used  a  measure  of  total  protein 
loaded.  These  results  are  representative  of  two  independent 
experiments.
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Figure 3.18 Knockdown of endogenous hECSIT in the U373 
cell  line  does  not  affect  the  processing  of  p105 
following LPS stimulation.
U373  cells  were  polyclonally  transduced  with  hECSIT-specific 
lentiviral  shRNA  or  Control  shRNA.  Cells  were  cultured  in  the 
presence of  selective  reagent  puromycin  (5μg/ml).  Knockdown of 
endogenous  hECSIT  was  checked  by  immunoblotting.  Once 
achieved,  the  cells  were  then  treated  with  LPS  (100ng/ml)  for 
various time points (5,10, 30, 60, 180mins). Cell lysates were then 
generated and subjected to SDS-PAGE and subsequently to Western 
immunoblotting with  antibodies  against  p105/p50  and  hECSIT. 
β-actin  was  used  as  a  loading  control.These  results  are 
representative of two independent experiments.
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 Figure 3.19 hECSIT does not interact with Tpl-2.
HEK 293 T cells were transfected with 1 µg hECSIT-MYC and/or 1µg 
Tpl2-HA as indicated. DNA levels were normalised with empty vector 
pcDNA3.1. Cells lysates were harvested 24 h post-tranfection and 
immunoprecipitated  with  an  immobilised  anti-MYC  antibody. 
Immunoprecipitates  were  subjected  to  polyacrylamide  gel 
electrophoresis and subsequently to Western immunoblotting using 
an anti-HA antibody. They were subsequently probed with anti-MYC 
antibody to confirm the co-immunoprecipitation. Cell  lysates were 
also analysed by Western immunoblotting with anti-MYC antibody 
and  anti-HA  antibody  to  confirm  expression  of  the  constructs. 
c
Immunoprecipitation  blot  shown  above  is  representative  of  two 
independent experiments. 
4. Discussion
In  1999 Kopp et  al., described a  newly  identified  protein  termed 
ECSIT.  It  was discovered during a yeast two hybrid screen where 
TRAF6  was  used  as  the  bait  and  it  was  subsequently  found  to 
enhance  NFκB  activation  as  well  as  playing  a  role  in  MEKK1 
processing.  When  null  mutants  of  ECSIT  were  generated,  the 
embryos died on day E7.5 due to defects in mesoderm formation. 
There  were  striking  similarities  in  the  phenotype  of  ECSIT  null 
embryos and those that had BMPR1 gene deletions, leading to the 
discovery that ECSIT was essential in BMP signal transduction (Xiao 
et  al., 2003).  Since  then,  ECSIT  has  been  established  as  a 
predominantly mitochondrial located protein that is involved in the 
assembly  of  mitochondrial  complex  1  (Vogel  et  al., 2007).  The 
relevance of ECSITs mitochondrial location and its interaction with 
TRAF6  was  deciphered  by  West  et  al., (2011)  when  they 
demonstrated that TRAF6 and ECSIT are required for macrophage 
killing of intracellular bacteria. They showed that signalling through 
TLR 1, 2 and 4 in macrophages results in mitochondrial recruitment 
to the phagosome. TLR signalling also induces TRAF6 translocation 
to the mitochondria,  where it  can bind to and ubiquitinate ECSIT 
resulting in an enrichment of ECSIT to the mitochondrial periphery 
and  a  concomitant  increase  in  both  mitochondrial  and  cellular 
production  of  ROS,  required  for  killing  of  intracellular  bacteria. 
Macrophages deficient in TRAF6 and ECSIT fail to clear infection, as 
do  those  with  deficient  mitochondrial  production  of  ROS.  Such 
findings  have established ECSIT  as  key protein  in  TLR signalling, 
critical to innate immune clearance of bacteria. 
ci
All  previous studies  have focussed on the murine form of  ECSIT, 
mECSIT. While murine models are routinely used as in vivo models 
in  immunology,  the  distinct  difference  between  the  human  and 
murine immune systems means that results in murine models do 
not always translate directly to human models. Indeed in terms of 
TLR signalling,  while generally  there is  high level  of  conservation 
across human and mice there are differences in the TLR expression 
with 13 TLRs in mice and 11 in humans. Murine and human TLRs 
can  show  differential  recognition  of  ligands  .  It  is  therefore 
important  when  using  mice  as  experimental  tools  to  consider 
differences that may be present in human forms.  The human form 
of ECSIT, hECSIT, was cloned in the Moynagh Lab, who have since 
been  concerned  with  characterising  its  role  in  TLR  signalling. 
Despite being homologs of each other, hECSIT and mECSIT display 
opposing roles in NFκB activation. This has been shown extensively 
as part as ongoing research in the Moynagh lab (unpublished) and is 
briefly  exemplified  in  my work  (Figure  3.1).   mECSIT  can induce 
NFκB  activation   and  enhance  LPS-  and  IL-1β-induced  NFκB 
activation.  This  is  agreement  with  the  initial  characterisation  by 
Kopp et al.,  (1999) that mECSIT is a positive intermediate in NFκB 
activation. In contrast hECSIT fails to induce NFκB and displays mild 
inhibitory effects on its activation upon LPS and IL-1β stimulation. It 
is therefore proposed as a negative regulator of NFκB activation. 
In an effort to understand how hECSIT signalling differs from that of 
mECSIT, I set to uncover hECSIT interacting proteins. A proteomic 
screen  of  proteins  that  could  co-immunoprecipiatate  with  hECSIT 
was undertaken. This was considered as an unbiased approach of 
detecting  interacting  proteins,  as  it  would  survey  all  hECSIT 
interacting  proteins  within  the  cell  and  identify  them  by  mass 
spectrometry. The experiment required the large scale culturing of 
HEK293  T  cells  transiently  expressing  hECSIT  and  subsequent 
immunoprecipiation  of  hECSIT  and  its  interacting  proteins.  The 
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experimental model was restricted by low protein returns following 
the  co-IP,  even  after  pooling  of  samples,  limiting  the  amount  of 
protein  available  for  two-dimensional  electrophoresis  (2-DE) 
separation  (Figure  3.3).  From this  screen,  8  proteins  spots  were 
identified  as  coimmuniprecitiating  with  hECSIT  (Table  3.1).  No 
known ECSIT interacting partners were identified. This may be due 
to the low protein levels loaded or because these interactions were 
below the detection level of the assay. In addition, of the proteins 
separated by 2-DE, the majority are non-specific as they are present 
in  control  and  hECSIT  immunoprecipitated  samples.  The  high 
proportion of non-specific proteins may be masking the presence of 
specific interacting proteins, preventing their detection. In a repeat 
of  this  experiment in  the future,  in  addition  to loading increased 
protein amounts, further washing of the co-IP samples to remove 
non  specific  proteins  would  be  of  benefit.  As  mECSIT  has  been 
shown to have a predominately mitochondrial location, isolation of 
cell  lysates  into  mitochondrial  fractions  prior  to  performing  the 
coimmunoprecipiation  may also  increase the  detection  of  hECSIT 
partners. 
Of the 8 proteins subjected to mass spectrometry identification, 5 
were  identified  as  hECSIT,  indicating  that  hECSIT  is  present  in 
several forms within the cell. Probing gels with anti-hECSIT antibody 
confirmed the hECSIT can be detected at more than one point on 
the  gel  (Figure  3.4).  This  is  not  entirely  unexpected  as  ECSIT  is 
proposed  to  have  four  isoforms  due  to  alternative  splicing  of 
transcripts  (http://www.ncbi.nlm.nih.gov/sites/entrez?
db=geneandcmd=Retrieveanddopt=full_reportandlist_uids=51295). 
As post translation modification of proteins by phosphorylation and 
ubiquitination is so critical to TLR signalling, it could be postulated 
that these spots may represent post translational modified forms of 
hECSIT. However these questions were not addressed as part of my 
thesis, instead I focussed on the protein identified as ZNF419.  It 
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was chosen as a protein of interest due to the presence of a zinc 
finger domain within the protein. Several proteins involved in TLR 
signalling contain zinc finger domains, such as ZCCHC11, Gfi1 and 
A20 (Jaaflela  et al., 1996; Minoda et al., 2006; Wallis  et al., 2003). 
ZNF419 is characterised as a KRAB domain containing C2H2 zinc 
finger  protein,  which  is  the  largest  subfamily  of  the  zinc  finger 
family. KRAB domains are associated with transcriptional repression, 
indeed  KRAB  domain  proteins  have  been  previously  shown  to 
negative regulate innate immune signalling (Kamitani et al., 2011).
As  the  commercial  available  antibody  against  ZNF419  failed  to 
detect ZNF419 expression (Figure 3.5),  a  FLAG-tagged version of 
ZNF419  had  to  be  engineered.  When  the  interaction  between 
hECSIT  and  ZNF419-FLAG  was  probed  by  conventional  co-IP 
methods,  no  interaction  could  be  detected  (Figure  3.6).   This 
questioned  the  physiological  relevance  of  the  identification  of 
ZNF419  as  a  hECSIT-interacting  protein  by  mass  spectrometry. 
Increasing the stringency of criteria used for accepting protein hits 
from mass spectrometry  such as  percentage of  peptide  matched 
may prevent such false results in future screens. 
Considering  that  zinc  finger  domains  are  present  in  numerous 
proteins  relevant  to  TLR  signalling,  it  was  still  of  interest  to 
investigate  if  ZNF419  could  affect  NFκB  activity.  As  shown  by 
luciferase assay, ZNF419 does not play a role in the LPS, IL-1β or 
TNFα induced activation of NFκB (Figure 3.7) Recently, Broen et al., 
(2011),  measured the  levels  of  ZNF419 expression in  fibroblasts, 
keratinocytes  and proximal  tubular  epithelial  cells  and found the 
expression to be low. Interestingly they found that IFN-y caused an 
increase in ZNF419 expression in keratinocytes. 
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As mECSIT has been shown to be critical to BMP signalling (Xiao et 
al., 2003),  I  wanted  to  establish  if  hECSIT  has  a  role  in  BMP 
signalling  and  whether  it  would  act  comparably  with  mECSIT  to 
promote  BMP  signalling  or  act  differentially  as  it  does  in  NFκB 
signalling.  BMP signalling  from the cell  surface  to  the  nucleus  is 
propagated by the SMAD family of transcription factors which can 
regulate  gene  transcription  by  binding  to  the  promoter  of  BMP 
responsive  genes.  BMP  signalling  initially  activates  a  distinct 
subgroup of receptor regulated SMADs (R-SMADS), SMAD1, SMAD5 
and SMAD8 (SMAD1-5-8),  which  once activated can interact  with 
SMAD4 to induce gene transcription  . Xiao et al., (2003) discovered 
that mECSIT is critical to BMP signalling, it can basally interact with 
SMAD4 and interacts with SMAD1 in a BMP4 inducible manner to 
promote that transcription of BMP4 inducible genes, such as Tlx-2. 
My first approach to address the role of hECSIT in BMP4 signalling 
was to suppress endogenous hECSIT expression and investigate the 
effect  on  SMAD1-5-8  activation.  When hECSIT  is  suppressed,  the 
phosphorylation of SMAD1-5-8 is decreased (Figure 3.8).  As mECSIT 
mediates  its  effects  on  BMP  signalling  through  interaction  with 
SMAD proteins, it was of interest if hECSIT could similarly interact 
with SMADs. However no interaction between hECSIT and SMAD4 
could  be  detected  (Figure  3.8).  It  would  be  of  value  for  future 
studies to probe the interaction of hECSIT with other SMAD family 
members. This initial investigation into the role of hECSIT in BMP4 
signalling indicates that similar to mECSIT, hECSIT is involved in the 
positive regulation of BMP4 signalling. However the mechanism by 
which hECSIT achieves this and the result of hECSIT regulation of 
SMAD1-5-8  remain  unanswered.  More  extensive  studies  in  the 
future  will  address  if  hECSIT  interacts  with  any  members  of  the 
SMAD  family  and  how  hECSIT  regulates  the  expression  of 
BMP-inducible genes. 
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While  BMP4 primarily  signals  through  SMAD proteins,  it  can also 
signal through non-canonical SMAD-independent pathways (Yang et 
al., 2006).  Several  studies  have  shown  that  BMP4  can  mediate 
signalling by targeting the MEK1/2- p42/44 pathway (Li et al., 2012; 
Zhou  et al., 2007), and therefore I looked at the effect of hECSIT 
suppression on BMP4 induced p42/44  activity.  Interestingly  when 
hECSIT is knocked down, p42/44 exhibits drastically higher levels of 
phosphorylation under resting conditions compared to control cells 
(Figure 3.8). While control cells show induction of p42/44 activation 
upon BMP4 stimulation, cells with suppressed expression of hECSIT 
display no further induction. Similar results are found in response to 
TLR4 signalling (Figure 3.10), indicating that hECSIT is involved in 
the basal regulation of  p42/44 activity.  To further investigate the 
role of hECSIT in the regulation of MAPK activation other cells lines, 
such  as  HEK293  T,  HEK293  TLR4  and  U373  cells  which  display 
strong induction of MAPK proteins in response to proinflammatory 
signals were used.  
Considering that hECSIT and mECSIT display striking differences in 
their regulation of the transcription factor NFκB (Figure 3.2), it was 
of  relevance to  compare  the  roles  of  hECSIT  and  mECSIT  in  the 
regulation  of  MAPK  induced  transcription  factors.   Numerous 
transcription  factors  have  been  shown  to  be  targets  of  MAPK 
signalling including ELK-1, CHOP1, CREB, ATF4, c-fos, NFAT, STAT3 
and p53, with individual MAPK members showing overlapping and 
distinct targeting of their activation (Cargnello and Roux, 2011). To 
assess  if  ECSIT  could  regulate  MAPK  activation  of  transcription 
factors,  luciferase  assays  monitoring  the  activation  of  ELK-1  and 
AP-1 were preformed.  ELK-1 is a key target of p42/44, but can also 
be targeted by p38 and JNK. P42/44 can bind to and directly activate 
ELK-1  to  induce  immediate  early  genes.  One  such  target  gene 
encodes the protein c-fos, which can then form dimers with c-jun to 
form  the  AP-1  transcription  factor  .  JNK  is  also  critical  to  the 
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induction of AP-1 as it can directly bind to activate the AP-1 subunit 
c-jun. Heterodimeric complexes of AP-1 composed of c-fos and c-jun, 
can regulate numerous pronflammatory genes, including IL-1β and 
TNFα .  Similar to their opposing roles on NFκB activation,  hECSIT 
and mECSIT display differential  effects on the activation of  ELK-1 
and  AP-1.  mECSIT  augments  the  activation  of  ELK-1  and  AP-1 
(Figure 3.11) While hECSIT displays marginal inhibitory affects on 
ELK-1  and  AP-1  activation,  this  is  consistent  with  its  inhibitory 
effects on the upstream regulator p42/44.
The initial studies on mECSIT had proposed mECSIT to be the key 
linker  protein  that  couples  TRAF6  to  MAPK activation  as  mECSIT 
could bind both TRAF6 and MEKK1 (Kopp et al., 1999). mECSIT was 
also indicated to play a role in MEKK1 processing. Consequently I 
wanted  to  determine  if  hECSIT  could  regulate  MEKK1-induced 
activation of the MAPKs. While there are negligible effects on p38 
and JNK activation, hECSIT shows strong inhibitory effects towards 
p42/44 phosphorylation (Figure 3.13). To validate the results alluded 
to  by  the  overexpression  studies,  RNAi  technology  was  used  to 
suppress  the  expression  of  endogenous  hECSIT.  hECSIT  specific 
siRNA and lentiviral shRNA was therefore  employed. Supression of 
endogenous  hECSIT  again  specifically  impacts  p42/44  activation, 
resulting  in  increased  basal  and  proinflammatory  induction  of 
p42/44  phosphorylation  (Figure  3.14,  3.15,  3.16  and  3.17)  The 
overexpression studies and the complementary siRNA and shRNA 
studies  define  hECSIT  as  being  a  negative  regulator  of  p42/44 
phosphorylation.
The discriminatory regulation of p42/44, and not the p38 or JNK, by 
hECSIT  indicates  the  hECSIT  functions  by  targeting  proteins  that 
operate solely in the p42/44 pathway. Potential candidates include 
MAPKKK, MAPKK, DUSP and certain scaffold proteins (Kolch, 2005). 
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The activation of p42/44 in response to growth factors primarily is 
through the Ras-Raf pathway, where Raf acts a MAPKKK to activate 
MEK1/2 which can then subsequently activate p42/44 (Kolch, 2000). 
However  in  terms  of  immune  signalling,  where  proinflammatory 
stimulation  leads  to  p42/44  activation,  pathways  involving  other 
MAPKKK  such  as  MEKK1  and  Tpl2  are  employed  (Symon  et  al., 
2006). Tpl2 was of interest to this study as it specifically acts on 
p42/44 and not p38 or JNK. Under resting conditions the activity of 
Tpl2  is  regulated  by  its  interaction  with  the  NFκB subunit  p105, 
which prevents Tpl2 from interacting with and activating MEK1/2. In 
response  to  proinflammatory  signals,  IKK  proteins  induce  the 
processing of p105 protein to the p50 form. This partial degradation 
of  p105,  releases  Tpl2  allowing  it  to  activate  the  MEK1/2-p42/44 
pathway (Robinson et al., 2007). These signalling events have been 
shown to be critical to the production of LPS induced TNFα and IL-1β 
(Rousseau et al., 2008). I set out to investigate if hECSIT was acting 
at the level of Tpl2 to regulate p42/44 activity.  
As the NFκB subunit p105 has a critical role on the regulation of Tpl2 
activity, I examined whether the suppression of endogenous hECSIT 
by hECSIT shRNA affected the levels and processing of p105 to p50. 
However no significant differences between the control and hECSIT 
shRNA samples could be witnessed (Figure 3.18). In addition to its 
interaction  with  p105,  Tpl2  also  interacts  with  ABIN-2 
(Papoutsopoulou et al., 2006) and the p38 isoforms p38gamma and 
p38delta (Risco  et al., 2012).  In macrophages,  deletion of  any of 
these components  results  in Tpl2  degradation,  preventing p42/44 
activation. As the interacting partners of Tpl2 are so critical to its 
activation of p42/44, it was proposed that hECSIT could form part of 
this  complex  to  regulate  Tpl2  activity.  However  no  interaction 
between  hECSIT  and  Tpl2  could  be  detected  when 
co-immunopreceipations were preformed (Figure 3.19)
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 Although hECSIT suppression has no effect on p105 processing and 
does  not  interact  with  Tpl2,  it  is  still  possible  that  hECSIT  may 
regulate  Tpl2  activity  resulting  in  the  augmented  p42/44 
phosphorylation  that  is  observed  under  conditions  of  hECSIT 
suppression. Future studies should probe any possible relationship 
between  hECSIT  and  Tpl2  in  depth  starting  by  investigating  the 
phosphorylation  of  Tpl-2  in  response  to  proinflammatory  signals 
when hECSIT is suppressed. GSKβ3 is another viable candidate for 
mediating the regulatory effects of hECSIT on the p42/44 pathway. 
GSKβ3 is a negative regulator of p42/44 activity and it is active in its 
unphosphorylated state (Wang et al., 2006). Signalling through the 
PI3K  pathway,  phosphorylates  and inactivates  GSK3β  to  promote 
the activity of p42/44. It will be of great interest to assess if hECSIT 
suppression  affects  the  activity  of  GSKβ3.  The  basal  activity  of 
GSKβ3 in its unphosphorylated state will be of special interest given 
the  increased  basal  phosphorylation  of  p42/44  when  hECSIT  is 
suppressed. `
While  my  thesis  has  focussed  on  the  Tpl2  pathway  of  p42/44 
activation,  hECSIT  may  be  relevant  to  the  Ras-Raf  pathway. 
Interestingly a tandem affinity purification (TAP) screen undertaken 
recently by members of the GHOSH lab has shown that mECSIT can 
interact  with  rac-1  (West,  A.  2011-  PhD  thesis).  They  used  a 
C-terminally  TAP-tagged  ECSIT  expression  vector  containing  both 
streptavidin and calmodulin binding peptides. After TAP-purification 
of  mECSIT  and  its  binding  partners,  samples  were  separated  by 
SDS-PAGE  and  identified  by  mass  spectrometry. A  possible 
interaction between hECSIT and Rac-1 is highly relevant to hECSITs 
regulation  of  p42/44.  Rac-1  is  a  member  of  the  RHO  family  of 
GTPase and has been shown to be activated in  response to TLR 
signalling.  Importantly  it  has  been  shown  to  phosphorylate  PAK, 
which can in turn phosphorylate MEK1 to enhance MEK1 interaction 
with  ERK2  (Eblen  et  al., 2002;   2004).  In  a  negative  feedback 
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mechanism ERK is proposed to also phosphorylate MEK1, preventing 
PAK phosphorylation  of  MEK1.  Based on hECSIT  inhibitory  role  in 
p42/44  phosphorylation,  it  is  plausible  to  propose  that  the 
interaction  of  hECSIT  with  Rac-1  under  resting  conditions  may 
regulate Rac-1 activity. Indeed the p42/44 inhibitor RKIP has been 
shown  to  act  in  such a  way  (Trakul  et  al., 2005).  Under  resting 
conditions  it  binds  to  Raf  and  MEK  preventing  their  physical 
interaction and Raf-induced activation of MEK. RKIP interaction with 
Raf  is  also  thought  to  prevent  PAK  induced  activation  of  Raf. 
Mitogenic stimulation results in the dissociation of RKIP and Raf to 
allow MEK1/2  activation.   Interestingly  RKIP  like  hECSIT  can  also 
target  NFκB  activation  (Yeung  et  al., 2001).  Thus  future 
investigations of the molecular and functional interactions of hECSIT 
and rac-1 will  be of  great interest in the context of  signalling by 
mitogenic and proinflammatory stimuli.
mECSIT was identified over ten years ago, but to date there are no 
published reports on the human form of hECSIT. Here I show that 
hECSIT specifically targets the p42/44 branch of MAPK signalling. It 
acts  as  a  negative  regulator  of  p42/44  phosphorylation,  and 
functions  under  resting  conditions  and  when  proinflammatory 
signalling  pathways  are  induced.  How  hECSIT  inhibits  p42/44 
phosphorylation  remains  unknown,  as  does  the  physiological 
consequences on p42/44 signalling when hECSIT is suppressed. In 
addition  West  et  al., (2011)  showed that  TRAF6 ubiquitination  of 
mECSIT  was  required  for  ECSIT  signalling.  Whether  the 
ubiquitination status of hECSIT, or indeed its phosphorylation status, 
is relevant to its regulation of p42/44 needs to also be addressed. 
The  importance  of  mitochondrial  signalling  in  innate  immune 
signalling is gaining more appreciation. mECSIT is now known to be 
a  predominately  mitochondrially  located  protein,  with  its 
mitochondrial  location  critical  to  its  signalling.  Establishing  the 
cellular location of  hECSIT signalling and its signalling partners is 
cx
essential to understanding hECSIT signalling and may explain the 
opposing role of hECSIT and mECSIT on NFκB and p42/44 activity.
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